Call for proposals 2027 – JTC10

Nano and advanced technologies for developing Diagnostic tools to improve the detection and the clinical management of non-communicable diseases

NanoDiagNCD



Call Text

DEADLINES

19 January, 2027 (12:00, CET) - SUBMISSION OF PRE-PROPOSALS

9 June 2027 (12:00, CEST) - SUBMISSION OF INVITED FULL-PROPOSALS

Link to electronic proposal submission

https://ptoutline.eu/app/E4H-NANODIAGNCD

For further information, please visit us on the website: https://era4health.eu/

or contact the Joint Call Secretariat (JCS):

The French National Research Agency
Dr. Sandra Sinnassamy / Dr. Martine Batoux
+33 8 11 42 80 00 / +33 1 73 54 81 40
NanoDiagNCD@anr.fr

Funded by the European Union under the Horizon Europe Framework Programme. Grant Agreement N°101095426.
Version n°2

Content

Definitions 4
Acronyms 6
Aim and ambition of ERA4Health 7
Rationale 8
Aim of the call 8
Expected Impact 10
General conditions for application 10
Participating countries and respective funding organisations 11
Application 12
Eligibility criteria 12
Size of the consortium 13
Financial and legal modalities 14
Submission of joint proposals 15
Further information 16
Evaluation and decision 16
Eligibility check and evaluation procedure 16
Formal check and evaluation of pre-proposals 16
Formal check and evaluation of full proposals 16
Evaluation Criteria 17
Scoring system 18
Rebuttal stage 19
PRP meeting 19
Ethical clearance 19
Decision 20
Redress procedure 20
Responsibilities, Reporting requirements and Dissemination 21
Consortium Agreement 21
Ethics 21
Gender mainstreaming 21
Open Science 22
Scientific publications: 22
Research data management 22
Progress report 23
Communication 23

Confidentiality 24
General Data Protection Regulation 24
ERA4Health Responsible Innovation Journey Guide/ (RRI Guidelines) 25
ANNEX I 26
Belgium 26
Egypt 28
France 31
Hungary 34
Israel 36
Italy 37
Latvia 39
Lithuania 41
Norway 43
Poland 45
Romania 49
Slovakia 51
Spain 56
Taïwan 69
The Netherlands 70
Türkiye 75

Definitions

Application
The call application is composed of the pre-proposal or the full proposal, on the first or second stage respectively, and the information filled on the PT-outline submission platform.

Call Steering Committee
Committee composed of one representant of each funding organisation participating in the call with funds. The CSC is responsible for all decision taking in the call.

Collaborator
Institution that does not request funds from any of the participating funding organisations; they are self-funded institution. See section of the call text "Application – Size of the consortium" for details about the maximum number of collaborators allowed per consortium and participation conditions.

Consortium
Group of partners and collaborator(s) submitting a proposal together to the call. See section of the call text "Application - Eligibility Criteria" for details about the consortium composition. The consortium must be represented by a coordinator chosen within the different partners.

Coordinator
Institution who takes primary responsibility for the design conduct and reporting of the study and who is responsible for the overall project coordination.

Partner
Institution eligible for requesting funding from one of the funding organisations participating to the call.

Principal investigator (PI)
Each institution participating to a consortium is represented by a single Principal Investigator.

PT-Outline
Submission platform. All applications must be submitted on the submission platform. The coordinator is responsible for filling the application on PT-Outline. It is advised to start completing the application on the platform early as a lot of information about the partners must be entered. On the last section, the coordinator will be asked to upload the pre-filled proposal template (PDF format).

Pre/ Full proposal template
Template in word format that the applicants must follow exactly (no extra documents such as supporting letters or extra CV, respect of the paragraph maximum length, etc). The pre-proposal template is available on the call page of the ERA4Health website. The full proposal template will be sent directly to the consortium invited to the second step of the call.

Responsible Research and Innovation (RRI)
It is the process of engaging with the social, political, environmental or ethical complexities of research and innovation. Further information can be found in ERA4Health's Guidelines for RRI.

Widening concept
Between the two steps of the call, each consortium invited to the second stage of the call and that has not reached the maximum number of partners yet, will have the opportunity of adding one new partner from underrepresented countries (name of countries will be communicated by the JCS

concomitantly with the results of the first step of the call). It is mandatory for the new partner to contact its national funding organizations prior to submission of the full proposal to confirm their eligibility for funding.

Acronyms

ARRIVE Animal Research: Reporting of In Vivo Experiments

CA Consortium Agreement

CSC Call Steering Committee

DMP Data Management Plan

EC European Commission

ECN Early Career Network

ECS Early Career Scientist

FAIR Findability, Accessibility, Interoperability, and Reusability

GDPR General Data Protection Regulation

IP Intellectual Property

JCS Joint Call Secretariat

JTC Joint Transnational Call

KET Key Enabling Technology

NCD Non-Communicable Disease

NGO Non-Governmental Organisation

ORE Open Research Europe

PI Principal Investigator

PRP Peer Review Panel

RRI Responsible Research and Innovation

SO Specific Objective

SRIA Strategic Research and Innovation Agenda

Aim and ambition of ERA4Health

The Partnership "Fostering a European Research Area for Health" (ERA4Health) aims at establishing a flexible and effective coordination between funding organisations in the European Research Area (ERA) for Health and Well-being. This Partnership brings the opportunity to increase European transnational collaborative research funding by creating a funding body for joint programming in priority areas addressing European Public Health Needs.

The general objective of ERA4Health is to reach an effective joint approach and generate knowledge and products (e.g. preventive guidelines, medical protocols) in the identified research areas as outlined in ERA4health Strategic Research and Innovation Agenda (SRIA)[1]. To achieve this, a comprehensive network has been created which aims at strengthening and expanding the existing conducive ecosystem.

In this light, ERA4Health gathers public funders of health research in the European Research Area including the European Commission that jointly identify and implement a common funding strategy in priority areas to advance health research and develop innovation.

ERA4Health has 4 specific objectives:

- SO1. Support relevant medical research including clinical fields and intervention areas (prevention, diagnosis, treatment),
- SO2. Improve the utilisation of existing health technologies in clinical practice,
- SO3. Build capacity, in particular in conducting Investigator-Initiated Clinical Studies at European scale,
- SO4. Implement and advance the practice of Responsible Research and Innovation (RRI) across the breadth of the programme.

[1] https://era4health.eu/assets/docs/ec_rtd_he-partnerships-era-for-health-1.pdf

Rationale

Accurate and timely diagnosis serves as the foundation for nearly all clinical decisions. According to the WHO[2], diagnostic results influence approximately 70% of healthcare interventions. However, despite their pivotal role, diagnostic services receive only 3–5% of total healthcare funding. Non-communicable diseases (NCDs), including cardiovascular diseases, cancer, diabetes, and chronic respiratory conditions, represent the leading cause of death worldwide, accounting for 74% of global mortality (WHO). Effective management of these diseases relies heavily on availability of diagnostic tool for the whole continuum of care. To build resilient healthcare systems and achieve universal health coverage, it is imperative to expand access to and availability of diagnostic services, ensuring they are prioritized as a critical component of healthcare delivery.

Over the last few years, Europe has successfully contributed to many of the achievements in nanotechnologies such as nano-enabled in vivo imaging, high-throughput diagnostics, biosensing, lab-on-a-chip systems, point-of-care devices, or wearable and decentralized diagnostic solutions. Those technologies have served as the foundation for developing the new generation of diagnostic tools. However, a critical issue concerns the difficulty for those involved in the research and technology development to effectively turn basic knowledge into industrial and clinical innovations. In order to bridge this gap, it is essential that efforts are made to support ground-breaking projects in which academia, industry and clinical research collaborate from the very start i.e. the conception of the project. In addition, requirements as scalability, manufacturability, standardization, affordability, accessibility, regulatory readiness, interoperability, and integration into diverse healthcare systems should be prioritized from the outset. By embedding these considerations early into the development process, Europe will expedite the deployment of nanomedicine solutions, ensuring they deliver tangible clinical benefits and broader societal impact.

Additionally, integrating nanotechnology with other cutting-edge technologies/Key Enabling Technologies (KET) could significantly improve diagnostic tools. The concept of “cross-cutting KET” refers to the integration of different KETs in a way that creates value beyond the sum of the individual technologies. Cross-cutting KETs can lead to unexpected breakthroughs, fostering new technologies and, ultimately, innovative health market products. In Europe, the KET include (i) economic analyses of market trends and their contribution to solve societal challenges (ii) advanced manufacturing and materials (iii) micro- and nano-electronics (iv) micro- and nano- photonics (v) biotechnology (vi) advanced manufacturing systems (vi) artificial intelligence and (vii) other digital technologies.

Building on these challenges and opportunities, ERA4Health is launching a call to support nanotechnology research that bridges the gap between innovation and clinical implementation in development of diagnostic tools for NCDs.

Aim of the call

The aim of this call is to support translational research projects that develop application(s) of nanotechnologies, either solely or in combination with Key Enabling Technologies (KETs), to make significant strides in the development of diagnostic and theranostic tools for Non-Communicable Diseases (NCDs). Proposals should focus on developing and/or validating diagnostic and theranostic tools that are grounded in robust scientific evidence. The results obtained from these tools must enable the optimisation of the care continuum. This care continuum includes, among other things,

[2] https://www.who.int/health-topics/diagnostics#tab=tab_2

prevention, early disease detection, disease monitoring, treatment guidance, adverse effect and/or risk/benefit assessment.

The proposed research must define and validate performance benchmarks against existing diagnostic approaches to demonstrate added value in terms of sensitivity, specificity, accessibility, affordability, patient comfort, invasiveness and/or safety.

In addition, at any stage of the research and for all applications, translational and adoption requirements for nano-enabled diagnostic and theranostic solutions must be considered. This includes scalability, manufacturability, standardisation, affordability, accessibility, cost-effectiveness, regulatory readiness, interoperability, and integration across different healthcare systems.

In case of the development of theranostic tool(s), the proposed approach must apply a diagnostic-first principle, where diagnostic must serve the therapeutic choice.

Beyond the research topic the following points should be considered:

- Proposals must clearly demonstrate the potential health impact(s) as well as the added-value of transnational collaboration (e.g. sharing of expertise and resources (models, databases...), harmonisation of data, access to innovative technologies, etc..) by emphasising the unique contribution of each partner.
- Proposals should clearly state the expected scientific, societal and economic impact.
- Studies of KETs, other than nanotechnologies, are only possible if they are used in complement or in combination with nanotechnologies. If AI is used as a Key Enabling Technology, it should contribute to the functionality, performance, or clinical implementation of the diagnostic platform. It should go beyond stand-alone data analysis.
- At the end, projects should fall within TRL 4-6, although to be realistic and coherent with the characteristics of the call, projects should propose advancing a maximum of two TRL levels during their lifetime. Industry and clinician's engagement should be appropriate for the TRL range being investigated.
- The involvement of relevant stakeholders (e.g. citizens and/or patients' representatives, regulators, economists) in the project is strongly recommended from the conception stage to the implementation and the dissemination of the project and its results in order to apply bedside to bench to bedside principle and allow a patient centred solution. They can participate as partners (if eligible for funding by their national/regional funding organisation), as collaborators (participation with own budget) or as part of an advisory board.
- Applicants should consider potential moderators of effects such as age, sex, gender and ethnic or other relevant demographic or socioeconomic features/differences when appropriate for the topic of the proposal.
- Where relevant, cellular, 3D and patients' models should be preferred to animal models. The use of animal models must be justified.
- Applicants should make use of existing biobanks and existing cohorts, if applicable. Otherwise, it should be explained why existing biobanks/ cohorts are not used.
- The consortia are required to consider the gender balance in the composition of the consortia and to balance the responsibilities between genders.
- Early Career Scientists (Master, PhD and post-docs) are encouraged to participate in the consortium.

EXCLUSION :

- Proposals where nanotechnology is not central
- Discovery of new biomarkers. However, the development of known biomarkers is allowed such as technological advancements to improve the performance of existing biomarker-based tests, integration of multiple known biomarkers into single platforms, optimization for a different application, etc.
- Infectious diseases are excluded but studies on chronic diseases resulting from past infectious diseases are allowed.

Expected Impact

The results of the funded projects will significantly enhance diagnostic precision and enable implementation of personalized therapeutic strategies, empowering clinicians to make faster, more accurate, and patient-specific decisions throughout the care continuum. These outcomes will drive a shift toward predictive, preventive, and integrated care models, ensuring earlier identification of disease progression, treatment resistance, or adverse effects. They will also establish advanced benchmarks for diagnostics, delivering improved sensitivity, specificity, clinical utility, and patient stratification, alongside enhanced safety and usability.

The impact of these projects will lead to measurable improvements in patient management, prognosis, and quality of life, particularly for those with chronic conditions. Patients will gain access to diagnostics closer to their point of care, whether in primary care, outpatient settings, or home-based monitoring, ensuring both convenience and clinical effectiveness. They will experience the benefits of sustainable, ethical innovations that prioritize welfare and meaningful clinical impact. Trust in the healthcare system will be strengthened through patient-centred solutions.

General conditions for application

The initial duration of the projects will be 36 months.

Proposals **must clearly demonstrate the added-value of transnational collaboration** i.e. sharing of resources (models, registries, diagnosis, etc.), harmonisation of data, sharing of specific know-how and/or innovative technologies.

Proposals should follow the principles of Responsible Research and Innovation (RRI). All consortia must show how they will engage with and address the relevant social, ethical, political, equity, environmental or cultural dimensions of the proposed research. The proposal template and ERA4Health Responsible Innovation Journey Guide (link to full guide) further support you on how RRI and complementary sets of ideas can be approached. You find proposal relevant part of the guide below.

Research supported by ERA4Health must respect fundamental ethical principles. Applicants have to fill an ethical grid and describe any potential ethical aspects of the work to be carried out, and how the

project will fulfil applicable requirements in institutional, national and European Union legislation (including the ethical standards and guidelines of Horizon 2020/Europe[3]).

When considering the use of generative artificial intelligence (AI) tools for the preparation of the proposal, it is essential to exercise caution and careful consideration. Further information on the European Commission's recommendations can be found here in these guidelines[4].

The individual project partners of the joint applications should be complementary, and the proposed work should contain novel, innovative and ambitious ideas with a high application potential for the end-users and/or with a high implementation potential to benefit of end-users/patients/citizens.

Furthermore, additional aspects need to be considered in the application:

- If appropriate: the design of the study (sample collection, statistical power, interpretation, relevant models for hypothesis validation) must be well justified and should be part of the proposal.
- For small-scale clinical studies up to phase 2: strategies for recruitment, retention, assessment, and analysis must be included. The study design and objectives should take into consideration the population that would be needed to reach the objective of the study. Data supporting the recruitment numbers is recommended.
- In case of an exploratory animal/ small-scale clinical study up to phase 2, a detailed description is required as part of the full proposal application form (requirements are included in the Guidelines for Pre-clinical and small-scale clinical studies up to phase 2). The review panel will scrutinise this information as part of the formal evaluation criteria (1-Excellence) of full proposals. Assistance for provision of the information on experimental design can be found in the general ARRIVE guidelines[5].

Participating countries and respective funding organisations

The following participating funding organisations have agreed to fund this call for transnational research projects:

Countries	Funding organisations	Acronym	Contribution €
Belgium	Fund for Scientific Research-FNRS	F.R.S.- FNRS	300 000
Egypt	Academy of Scientific Research and Technology	ASRT	300 000
France	French Research Funding Agency	ANR	2 000 000
Hungary	National Research, Development and Innovation Office	NKFIH	200 000
Israel	Ministry of Health	CSO-MOH	320 000
Italy	Ministry of Health	IT MOH	500 000
Latvia	Latvian Council of Science	LCS	600 000
Lithuania	Research Council of Lithuania	LMT	300 000
Norway	Research Council of Norway	RCN	2 000 000
Poland	National Centre for Research and Development	NCBR	1 250 000

[3] https://ec.europa.eu/research/participants/docs/h2020-funding-guide/cross-cutting-issues/ethics_en.htm
[4] https://research-and-innovation.ec.europa.eu/document/download/2b6cf7e5-36ac-41cb-aab5-0d32050143dc_en?filename=ec_rtd_ai-guidelines.pdf
[5] https://journals.plos.org/plosbiology/article/file?id=10.1371/journal.pbio.1000412&type=printable

Romania	Executive Agency for Higher Education, Research, Development and Innovation Funding	UEFISCDI	1.000.000
Slovakia	Slovak Academy of Sciences	SAS	240 000
Slovakia	Centrum vedecko-technických informácií Slovenskej republiky CVTI SR	SCSTI	500 000
Spain	State Research Agency	AEI	800 000
Spain	Regional Ministry of Presidency, Healthcare and Emergencies of Andalusia	CPSEJA	250 000
Spain	Fundación Para El Fomento En Asturias De La Investigación Científica Y Tecnología/ Agencia de Ciencia, Competitividad Empresarial e Innovación Asturiana	FICYT/ SEKUENS	150 000
Spain	Institute of Health Carlos III	ISCIII	600 000
Taïwan	National Science and Technology Council	NSTC	810 000
The Netherlands	Dutch Research Council	NWO	2 500 000
Türkiye	The scientific and technological research council of Türkiye	TUBITAK	600 000

Table 1: Participating funding organisations.

Project partners will be funded by their respective national/regional funding organisations. Eligible costs and funding rules vary between the different funding organisations (see Annex I).

Support for Early Career Researchers

All project principal investigators (PIs; i.e. representatives of the coordinators and partners) are asked to encourage the Early Career Researcher(s) (ECR) who will be involved in the research projects to actively engage in the ERA4Health Early Career Network (ECN). The aim of the ECN is to foster the interaction, capacity and growth of ECR involved in ERA4Health-funded projects. Different networking, training and capacity building activities dedicated to ECR will be organised and implemented during the runtime of the projects.

To facilitate participation of the ECR in the ECN, the coordinators and PIs should (I) include travel costs for the project's ECR dedicated to the ECN activities in the proposal and (II) allow the ECR to dedicate a small amount of their working time to the ECN. In addition, the research consortia are invited to include training activities for Early Career Researcher into their proposals. Examples of training activities are mobility and lab visits of ECR between partners of the consortium or implementation of summer school(s).

Application

Eligibility criteria

Joint research proposals may be submitted by applicants belonging to the categories A, B, C, or D described below. But the eligibility of the applicants depends on the national/regional regulations of the funding organisations participating to the call. Certain categories may not be eligible for funding by a specific funding organisation, please see Annex I and the guidelines for participants.

The four categories are:

- **A. Academia –** research teams working in public and private universities, other higher education institutions or research institutes.

- **B. Clinical/public health sector –** research teams working in hospitals/public health and/or other health care settings and health organisations, including primary health care.
- **C. Enterprises –** private companies of all sizes involved in health research and innovation.
- and **D. Operational stakeholders –** e.g. patient advocacy organisations, care providers, regulators, ... In line with the concept of RRI, operational stakeholders should be in a position to provide useful knowledge to the consortium, ensure the consortium's research is useful and translatable to their (or other) organisational contexts, and/or influence decision making or create change within their organisations. Operational stakeholders should be engaged in the research process from conception of the study to dissemination.

Each application must include partners applying for funding from at least two of the three categories A, B and C. The number of participants and their research contribution should be appropriate for the aims of the transnational research project and be reasonably balanced in terms of international participation. Each transnational collaborative project should represent the critical mass to achieve ambitious scientific goals and should clearly demonstrate an added value from working together. It is important to integrate partners from the category D in line with the aims of the proposal.
A partner search tool, called PartFinder, is available on the ERA4Health website[6] to help finding partners (filter by choosing the call name "ERA4Health NanoDiagNCD").

Size of the consortium

The following conditions apply to the composition of the transnational consortia:

- A minimum of 3 (three) eligible and a maximum of 5 (five) eligible partners from at least 3 (three) different countries participating in the call. In addition, at least 2 (two) eligible partners must be from different **EU Member States or Horizon Europe Associated Countries** participating in the call. The countries that are participating to the call and are not EU member states or Horizon Europe associated countries are Taiwan and Egypt.
- The maximum number of e**ligible partners** can be **increased up to 6 (six) or 7 (seven)** if they i**nclude 1 (one) or 2 (two) eligible partners**, respectively, **from** the following countries: **Slovakia**, **Lithuania, Taiwan and Türkiye.**
- **No more than 2 (two) eligible partners from the same country participating** in the call will be accepted within one consortium (regardless of the funding organisation).
- **A maximum of 2 (two) collaborators per consortium.** Collaborators are self-funded institutions: i.e. that do not request funds to any of the participating funding organisations (e. g. institutions from non-funding countries or institutions which are not fundable according to national/regional regulations of the participating funding organisations). The following conditions apply for collaborators:
    - Clear added value for the research project, this should be demonstrated in the proposal.
    - Secure own funding for participation with clear evidence in the proposal that this is already in place.
    - A letter of commitment of the collaborator(s) needs to be included as an annex to the pre-proposal/ full proposal.
    - A collaborator cannot be work package leader.

[6] https://era4health.eu/partner-search/

ERA4Health is cooperating with the Maltese funding agency Xjenza Malta. Through the Access2Partnerships (A2P) Scheme, Malta-based researchers can participate in the ERA4Health Call as partners on own funds and may be eligible for up to €300,000 per project to support their involvement in a successfully selected proposal, subject to a successful national application to Xjenza Malta. Further information on the national application procedure, specific scheme deadlines, eligibility requirements, applicable conditions and submission requirements can be found on Xjenza Malta's Access2Partnerships (A2P) Scheme webpage.

Total number of partners requesting funding (eligible partners)	**3-5**	**6**	**7**
Eligible partners from underrepresented countries	No restriction	At least 1	At least 2
Maximum number of collaborators	2	2	2

Table 3: Possible composition of a research consortium

Each project consortium must nominate **a project coordinator** from the participating principal investigators (NOT a collaborator). The project coordinator will represent the consortium externally and will act as contact person for the Joint Call Secretariat (JCS). The coordinator will be responsible during the entire process for the internal scientific coordination – management, overseeing IPR issues, reporting, and communication with the JCS.

Each principal investigator can submit either 1 (**one) proposal as project coordinator or up to 2 (two) proposals as simple partner** (i.e. the coordinator of a proposal cannot be partner in another proposal). Please note that some funding organisations accept only one submission per PI regardless of the role. Applicants are therefore strongly encouraged to contact their national/regional contact points to check their national/regional eligibility rules before submission (see Annex I).

Financial and legal modalities

Project partners will be funded by their relevant national/regional funding organisations. Therefore, eligible costs, funding rules and the type of studies allowed will vary between the respective funding organisations (see Annex I). Due to these differences, **it is highly recommended that each project partner defines its own budget in accordance with the funding rules of its own country/region.**

For information on the specific funding rules and eligibility criteria of the national/regional funding organisation:

- Carefully read Annex I and the national/regional announcements of the call
- In addition, **each applicant is strongly advised to reach out to their relevant funding organisation contact person before applying;** please note that for some countries/regions it might be mandatory.

Please note that if a partner requesting funding is found to be non-eligible at any step of the process by one of the funding organisations, the entire proposal could be rejected without further review.

Submission of joint proposals

There will be a two-step submission and evaluation procedure for joint applications, i.e. pre-proposals and full proposals, and the full proposal review process will be complemented by a rebuttal stage. For both submission steps, one joint proposal document (in English) must be prepared by the partners of a joint transnational consortium and must be submitted to the JCS by uploading it on the electronic submission system by the project coordinator.

The two-step application process will have the following timeline:

17 November 2026	**Publication of NanoDiagNCD call**
19 November 2026	**Webinar Infoday**
19 January 2027, before 12h00 CET	**Deadline for pre-proposal submission**
14 April 2027	Communication of the results of the pre-proposal assessment (invitation for full proposal)
15 April 2027	Webinar for applicants invited to submit a full proposal
9 June 2027, before 12h00 CEST	**Deadline for full proposal submission**
26 August – 6 September 2027	**Rebuttal stage**
End of October 2027	Communication of the funding decisions to the applicants
December 2027 – May 2028	**Expected project start** (subject to national procedures)

Table 1: Timeline application process

The pre-proposal template will be available on the ERA4Health website. The template for the full proposal stage will be sent to the project coordinator by the JCS with the invitation to submit a full proposal. Pre-proposals or full proposals submitted without using the relevant template will be declared non-eligible.

Pre-proposals, full proposals and rebuttal letters submitted after the deadline will be rejected.

If applicable, a proposal should be submitted together with a legal/ethical approval document according to the concerned country's/region's regulations.

For applicants from specific countries/regions, it might be mandatory to submit additional national/regional proposal and/or other information before the deadline of this call, directly to the national/regional funding organisations. Therefore, applicants are strongly advised to check their funding organisations specific regulations (See Annex I for more details) and reach out the contact person of the appropriate funding organisation.

The Call Steering Committee (CSC, composed of one representative/proxy from each funding organisation participating in the call with funds) will take all lawful steps to ensure confidentiality of the information and documents obtained during the evaluation and selection procedure of the joint call.

Applicants that are invited to submit a full proposal are **strongly encouraged to participate to the webinar scheduled on 15 April 2027** and to **use the mentoring service provided by EATRIS** (more information will be sent to the selected consortia for the submission of a full proposal).

For the submission of full proposals, **the widening concept** will be applied. It will therefore be possible, but not mandatory, to add partners that are eligible for funding by certain funding organisations (with low number of eligible applicants at the first step). The inclusion of a new partner should be relevant for the proposal and the new partner should be well integrated in the consortium. The list of funding organisations/countries will be provided by the JCS when the results of the first step will be communicated to the coordinators. The maximum limit of 7 partners within the consortium must still be respected. Finally, **it is mandatory for the PI of the new partner to contact its national funding organisation prior to submission of the full proposal and receive approval** (see contact details in Annex I of the call text). A deadline will be provided in the information received by the coordinators.

Further information

For additional information regarding the call's general eligibility rules, please contact the JCS; for additional information regarding national/regional rules, please contact your national/regional funding organisation Contact Person for (see Annex I).

Evaluation and decision

Eligibility check and evaluation procedure

Formal check and evaluation of pre-proposals

The JCS will check all proposals to ensure that they meet the call's formal criteria (date of submission; number and category of participating countries; inclusion of all necessary information in English; appropriate limits on length). In parallel, the JCS will forward the proposals to the national/regional funding organisations, which will perform a check for compliance with national/regional regulations.

Each proposal passing the eligibility check (JCS and country/region) will only be evaluated at a central level and not at the level of each funding organisation.

Each proposal will be individually evaluated by three reviewers for a first evaluation (see evaluation criteria below). The reviewers will perform the assessment of the pre-proposal and complete a written evaluation form with scores and comments for each evaluation criterion. Based on the scores in the written evaluations a ranking list will be established. Potential conflicts of interests of the evaluators will be taken into consideration during the allocation of the proposals. The CSC members will meet to decide which proposals will be invited to submit a full proposal based on the reviewers' recommendations while ensuring a reasonable balance of requested and available national/regional budgets. Pre-proposals which do not pass this assessment will not be invited for the full proposal stage. All consortia will receive the three remote evaluations.

Formal check and evaluation of full proposals.

The JCS will check the full proposals to ensure that they meet the call's formal criteria and have not changed substantially from the respective pre-proposals before sending them to the reviewers. Any fundamental change between pre- and full proposals, e.g. concerning the composition of the consortium, the objectives of the project or the requested budget must be communicated to the JCS

and to the national/regional involved funding organisations. In exceptional cases, these changes may be admitted if detailed justification is provided and if they are accepted by the CSC.

Each full proposal will be allocated to three reviewers taking into consideration the potential conflicts of interest. The reviewers will perform the assessment of the full proposal and complete a written evaluation form with scores and comments for each criterion (see evaluation criteria below). During a Peer Review Panel (PRP) meeting, the reviewers will discuss all proposals and produce a ranking list of proposals recommended for funding.

Before the PRP members meet to discuss each **full proposal** in a PRP meeting, each coordinator is given the opportunity to read and answer the comments and evaluation of the reviewers (see section "Rebuttal").

During the entire evaluation process, the evaluators are not authorized to use AI tools to conduct their evaluation.

Evaluation Criteria

1. Excellence

a. Scientific quality of the proposal:
   - Significance of the research question.
   - Clarity and relevance of the objectives.
   - Credibility and clarity of the proposed approach and methodology (including power calculations, randomisation, blinding and bias, target group(s) studied, as well as approach to responsible research and innovation).
   - Expected progress beyond the state-of-the-art, clearly demonstrating an innovation potential.
   - Quality of the project consortium: international competitiveness of participants in the field(s), previous work and specific expertise of the participants, complementarity of the participants, benefit of the transnational collaboration.

b. Novelty and ambition (including translatability of the proposed research to human health).

2. Impact

a. Unmet public and societal need and potential impact of the expected research results for future clinical, public health, and/or other socio-economic health relevant applications including patients' needs and/or for industry (i.e. product development).

b. Added-value of transnational collaboration and potential for fostering international network: gathering a critical mass of patients, sharing of resources (biological material, models, databases, etc.), harmonisation of data, sharing of specific know-how and/or innovative technologies, etc.

c. Projects with high potential of applicability at short/medium term (end of the projects at TRL5: validation of demonstrators and prototypes in a realistic laboratory and/or TRL6: relevant simulated operational field environment): expected time for market and transfer to patient towards clinical and public health applications, pharmaceutical/health device applications,

other industrial applications including market and end user's scenario, quality of dissemination, exploitation and business plan. (when appropriate/applicable).

d. Participation/engagement with end-users such as patients, industry, clinicians (when appropriate/applicable).
e. *Effectiveness of the proposed measures to exploit and disseminate the project results (including management of intellectual property rights), to communicate the project results in a tailored manner to the different audiences (e.g. policy makers, industry, patients), and to manage research data where relevant.*

Sub-criterion 2e. will be evaluated at the full proposal evaluation stage only.

3. Quality and efficiency of the implementation

a. Feasibility of proposal and likelihood of successful completion of proposed research.
b. Coherence and effectiveness of the work plan (including appropriateness of the allocation of tasks, person and the timeframe).
c. Use of existing biobanks and existing cohorts (when appropriate/applicable).
d. Appropriateness of the management structures and procedures, including risk, innovation management and RRI and ethical considerations.
e. *Adequacy of the budget: appropriate distribution of resources in relation to project activities, partner's responsibilities and time frame.*
f. *Sustainability of the research capacities initiated by the project (e.g. FAIR data management, Open Science practices). Quality of Intellectual Property management.*

Sub-criterion 3e and 3f will be evaluated at the full proposal evaluation stage only.

Proposals not relevant to the call topic and objectives (out of the scope) will not be funded, independently of their scientific quality. Evaluation scores will be awarded for the three main criteria. Each criterion will be scored out of five. The weight of each of the three main criteria is equal.

Scoring system

Evaluation scores will be awarded for the three main criteria. Each criterion will be scored out of five. The weight of each of the three main criteria is equal.

0 = Failure. The proposal fails to address the criterion or cannot be assessed due to missing or incomplete information.

1 = Poor. The criterion is inadequately addressed, or there are serious inherent weaknesses.

2 = Fair. The proposal broadly addresses the criterion, but there are significant weaknesses.

3 = Good. The proposal addresses the criterion well, but a number of shortcomings are present.

4 = Very Good. The proposal addresses the criterion very well, but a small number of shortcomings are present.

5 = Excellent. The proposal successfully addresses all relevant aspects of the criterion. Any shortcomings are minor.

Only integer values are accepted.

A full proposal will be considered fundable if the threshold score for individual criterion is 3 points and the overall score at least 10 points.

Rebuttal stage

Before the PRP members meet to discuss the full proposals in a PRP meeting, each coordinator will receive the reviewers' assessments. This stage allows applicants to comment on factual errors or misunderstandings that may have occurred in the review process and to reply to reviewers' questions. However, issues not related to reviewers' comments or questions cannot be addressed and the work plan cannot be modified at this stage.

The applicants will have up to 12 days (26 August – 6 September 2027) for this optional response to the reviewers' comments. Answers sent after the notified deadline or not related with reviewers' comments or questions will be disregarded.

PRP meeting

The JCS will give the PRP members access to full proposals, reviews and rebuttals, avoiding any conflicts of interest. The PRP will meet to discuss each proposal and, after consideration of the evaluation criteria, external reviews, rebuttals, and their own reviews and discussions, the PRP will assign final scores, make a classification of the proposals, and rank proposals recommended for funding. The final summary review report prepared by the PRP members will be sent to the respective project coordinators.

Ethical clearance

After the PRP meeting, Ethics experts will remotely check the full proposals, which are recommended for funding by the PRP and selected for funding by the CSC, for alignment with ethical norms and regulations[7]. A meeting will also be organised for a discussion between the various ethics experts if serious or complex ethics issues are identified in at least one full proposal. If necessary, the ethics experts may ask the consortium for clarifications on the ethical points related to the proposed research approaches and for documents such as the patient consent form. The Ethics experts may highlight some vigilance points that need to be monitored during the implementation of the funded project. Only the proposals approved by both the scientific evaluation and ethical assessment (complying with all central Horizon Europe and regional/national ethical requirements), will be funded. In addition, projects involving human embryonic stem cells (hESC) or human embryos (hE) may not start without prior ethics review carried out by the European Commission and subsequent decision of the Horizon Europe Programme Committee.

[7] Reference to EU Regulation 2021/695 and how-to-complete-your-ethics-self-assessment_en.pdf (europa.eu)

Decision

A final decision, based on the ranking lists established by the PRP, available funding and the ethical clearance, will be taken by the national/regional funding organisations. The CSC will strive to fund as many of the top-evaluated collaborative projects as possible.

Project coordinators having submitted an eligible proposal will be informed about the funding recommendation regarding their proposal by the JCS and will receive a consensus report summarising the evaluation. The projects coordinators are responsible for sharing this information to their project partners.

Redress procedure

Applicants can appeal against the evaluation outcome if they suspect a breach in the application of the evaluation and selection procedures. This redress procedure only covers the procedural aspects of the evaluation and/or eligibility checks, including the national eligibility checks. The redress will not call into question the scientific or technical judgement of appropriately qualified experts.
In this case they shall submit their appeal to the JCS via email (NanoDiagNCD@anr.fr), up to 7 calendar days after the date of dispatch of the evaluation outcome email by the call secretariat at the end of each stage (first or second step). The proposal outcome email containing the results of the evaluation will give information on the appeals procedure, which is described below.

Admissibility of appeals

For an appeal to be admissible the following conditions must be met:
- The appeal must be submitted by the coordinator of the proposal to which the appeal relates
- Only one appeal per proposal will be considered
- The appeal must be submitted via email within the 7 calendar days deadline. The appeal must contain the following minimum information:

- The name of the call for proposals;
- The proposal acronym;
- The title of the proposal;
- A description of the alleged shortcomings of the evaluation procedure.

The appeal must demonstrate a procedural irregularity, factual error, manifest error of assessment, misuse of powers, or a conflict of interests. Appeals that do not meet the above conditions, or do not deal with the evaluation of a specific proposal or express mere disagreement with the result or the reasoning of the evaluation might be judged as not suitable for redress.

Procedure

Upon receipt of an appeal, an acknowledgement of receipt will be sent by the call secretariat within 7 calendar days. The acknowledgement shall report the redress process and the anticipated date by which a decision on the appeal will be communicated to the appellant.
All appeals received by the 7 calendar days deadline will be processed together and the decision will be communicated to the appellant within 10 calendar days from the deadline for submitting the appeals.

Responsibilities, Reporting requirements and Dissemination

Consortium Agreement

It will be the responsibility of the project coordinator to draw up a Consortium Agreement (CA) suitable to the project partners in order to manage the delivery of the project activities, finances, intellectual property rights (IPR), to handle confidential data (e.g. patient data) and to avoid disputes which might be detrimental to the completion of the project. Within a funded consortium, partners must grant each other access - under fair and reasonable conditions — to background needed for exploiting their results, unless the beneficiary that holds the background has — before acceding to the Agreement — informed the other beneficiaries that access to its background is subject to restrictions. The project consortium is strongly encouraged to sign this CA before the official project start date, and in any case the CA should be signed within the first 6 months of the project and provided to the JCS**.** Please note that national regulations may apply concerning the requirement for a CA (e.g. certain funding organisations may need the signed CA to release some funds). Further instructions will be provided by the JCS to the coordinators of the projects selected for funding.

Ethics

All funded partners must respect the fundamental principle of research integrity — as set out in the European Code of Conduct for Research Integrity[8].
This implies compliance with the following principles:

- reliability in ensuring the quality of research reflected in the design, the methodology, the analysis and the use of resources
- honesty in developing, undertaking, reviewing, reporting and communicating research in a transparent, fair and unbiased way
- respect for colleagues, research participants, society, ecosystems, cultural heritage and the environment
- accountability for the research from idea to publication, for its management and organisation, for training, supervision and mentoring, and for its wider impacts

All funded partners must ensure that persons carrying out research tasks follow the good research practices including ensuring, where possible, openness, reproducibility and traceability and refrain from the research integrity violations described in the Code. Activities raising ethical issues must comply with the additional requirements formulated by the ethics panels (including after checks, reviews or audits). Before starting the project and for the tasks raising ethical issues, the funded partners must have obtained all approvals or other mandatory documents needed for implementing the task, notably from any (national or local) ethics committee or other bodies such as data protection authorities. The documents must be kept on file and be submitted upon request by the coordinator to the granting authority. If they are not in English, they must be submitted together with an English summary, which shows that the documents cover the action tasks in question and includes the conclusions of the committee or authority concerned (if any).

Gender mainstreaming

The funded partners must take all measures to promote equal opportunities between men and women in the implementation of the funded projects and, where applicable, in line with the gender equality plan. They must aim, to the possible extent, for a gender balance at all levels of personnel assigned to the funded project, including at supervisory and managerial level.

[8] European Code of Conduct for Research Integrity of ALLEA (All European Academies).

Open Science

Scientific publications:

All funded partners must ensure open access to peer-reviewed scientific publications relating to their results. In particular, they must ensure that:

- at the latest at the time of publication, a machine-readable electronic copy of the published version or the final peer-reviewed manuscript accepted for publication, is deposited in a trusted repository for scientific publications
- immediate open access is provided to the deposited publication via the repository, under the latest available version of the Creative Commons Attribution International Public Licence (CC BY) or a licence with equivalent rights; for monographs and other long-text formats, the licence may exclude commercial uses and derivative works (e.g. CC BY-NC, CC BY-ND) and
- information is given via the repository about any research output or any other tools and instruments needed to validate the conclusions of the scientific publication.

Beneficiaries (or authors) must retain sufficient intellectual property rights to comply with the open access requirements.
Metadata of deposited publications must be open under a Creative Common Public Domain Dedication (CC 0) or equivalent, in line with the FAIR principles (in particular machine- actionable) and provide information at least about the following: publication (author(s), title, date of publication, publication venue); Horizon Europe or Euratom funding; grant project name, acronym and number; licensing terms; persistent identifiers for the publication, the authors involved in the funded projects and, if possible, for their organisations and the grant. Where applicable, the metadata must include persistent identifiers for any research output or any other tools and instruments needed to validate the conclusions of the publication.
All research projects funded by ERA4Health are eligible to publish on **the Open Research Europe (ORE)**[9] at no cost.

Research data management

The beneficiaries must manage the digital research data generated in the funded projects ('data') responsibly, in line with the FAIR[10] principles and by taking all of the following actions:

- establish a data management plan (DMP). The first DMP will be requested after 6 months from the official start of the project and a final version at the end of the project.
- as soon as possible and within the deadlines set out in the DMP, deposit the data in a trusted repository; if required in the call conditions, this repository must be federated in the EOSC[11] in compliance with EOSC requirements
- as soon as possible and within the deadlines set out in the DMP, ensure open access — via the repository — to the deposited data, under the latest available version of the Creative Commons Attribution International Public License (CC BY) or Creative Commons Public Domain Dedication (CC 0) or a licence with equivalent rights, following the principle 'as open as possible as closed as necessary', unless providing open access would in particular:
- be against the beneficiary's legitimate interests, including regarding commercial exploitation, or
- be contrary to any other constraints, in particular the EU competitive interests or the beneficiary's obligations under this Agreement; if open access is not provided (to some or all data), this must be justified in the DMP
- provide information via the repository about any research output or any other tools and instruments needed to re-use or validate the data.

[9] https://open-research-europe.ec.europa.eu
[10] https://www.nature.com/articles/sdata201618
[11] EU's Open Science Policy | European Open Science Cloud - EU Node

Metadata of deposited data must be open under a Creative Common Public Domain Dedication (CC 0) or equivalent (to the extent legitimate interests or constraints are safeguarded), in line with the FAIR principles (in particular machine-actionable) and provide information at least about the following: datasets (description, date of deposit, author(s), venue and embargo); Horizon Europe or Euratom funding; grant project name, acronym and number; licensing terms; persistent identifiers for the dataset, the authors involved in the funded projects, and, if possible, for their organisations and the grant. Where applicable, the metadata must include persistent identifiers for related publications and other research outputs.

Progress report

The project coordinator is required to submit, through ERA4Health electronic monitoring tool, an annual scientific progress report on behalf of the consortium to the JCS in March of each year, detailing how the project is progressing in relation to planned objectives. Furthermore, a final scientific report must be submitted within a period of two months after the project has ended. In addition to the reports, information related to some indicators related to the project may be collected on a platform/survey.

National funding organisations may also request financial and/or scientific annual progress reports and/or a final report on the project from the partners from their respective country.

In addition, **the coordinators of each consortium are required to participate** to a kick-off meeting and to two progress update meetings, one mid-term and one final status symposium, that will be organized by the JCS. **An appropriate travel budget should be included and justified in the financial plan for the proposa**l. In case some of the events are organised as an online conference, all partners of the consortia will be encouraged to participate.

Communication

The project coordinator will represent the consortium externally and will be responsible for all communication with the relevant ERA4Health bodies. The coordinator must promptly inform the JCS in case of ANY significant changes in the work plan or the consortium composition. The JCS will inform the relevant funding organisations, who will decide upon the proper action to be taken.

Project coordinators, upon notification, are required to deliver an abstract of their project suitable for communication and dissemination purposes.

For the effective contribution of the project to the objectives of the ERA4Health, the project coordinator should be available to participate in meetings/workshops with the aim of:

- exchanging project results;
- developing a joint strategy to coordinate and facilitate integration of the planned activities of ERA4Health;
- communicating results across ERA4Health.

Importantly, all funding recipients must ensure that all outcomes (publications, etc.) of transnational ERA4Health funded projects include proper acknowledgement of the ERA4Health partnership and the respective funding partner organisations.
"This project received funding from [name of funding organisations, or an acknowledgment as requested by your national/regional funding organisations] under the umbrella of the Partnership

Fostering a European Research Area for Health (ERA4Health) (GA N° 101095426 of the EU Horizon Europe Research and Innovation Programme)."
When using LinkedIn as a communication and dissemination platform, the consortium should use the hashtags #ERA4Health and #E4H_NanoDiagNCD.

All projects funded under this JTC are strongly encouraged to participate in networking and joint activities where appropriate. These activities could involve participating in joint workshops to exchange knowledge, develop and adopt best practices, or carrying out joint communication. They could also involve networking and joint activities with projects funded under other action of Horizon Europe or another EU programmes.

Confidentiality

The ERA4Health JCS takes all reasonable steps to ensure that information provided in the application is treated confidential.

The proposals will be handled confidentially by the JCS and by the national/regional funding organisations. In selecting the international experts for the PRP, the JCS shall endeavour to avoid any possible conflicts of interest.

Each expert will have to sign a declaration of confidentiality and absence of conflict of interest. In case of a conflict of interest, the reviewer will be withdrawn from evaluating the respective proposal. Conflicts of interest are managed and recorded throughout the evaluation process.

General Data Protection Regulation

The following Data Privacy Notice applies:

By submitting an application, the applicants consent to the use, processing and retention of their personal data[12], in accordance with article 6.1 (e) and (c) of the General Data Protection Regulation (GDPR) (2016/679) and for the purposes of:

- processing and evaluating the application where processing shall be lawful only if and to the extent that processing is necessary for the performance of a task carried out in the public interest or in the exercise of official authority vested in the controller,
- administering any subsequent funding award,
- managing the funding organisations relationship with them,
- analysing and evaluating the call,
- providing aggregate data to national and European surveys and analyses on the funded projects,
- and complying with audits that may be initiated by the funding organisations and the European Commission (or its agencies).

The members of the CSC may share applicant's data with third parties (some of which may be based outside the European Economic Area) in relation to the above activities including evaluators, auditors and the European Commission (or its agencies).

[12] Last name, first name of the researchers, date of birth, professional contact information, degree(s), position (current and previous), fields of activity, place of work, organisation, address(es), curriculum vitae, ORCID number, name and reference of projects, pre-proposals, project proposals (scientific document, administrative and financial appendix).

The members of the CSC may link the data that funding recipients provide in the application with national, bibliographic or external research funding data which are available through public subscription-based databases (e.g. Scopus, Web of Science, etc.) or other national / open datasets.

ERA4Health Responsible Innovation Journey Guide/ (RRI Guidelines)

Indeed, responsibility in health innovation is a **shared commitment across the quadruple helix**: academia generates knowledge, government funds and regulates, industry develops and distributes, and civil society articulates what is needed and what is acceptable. Few health innovations reach patients through any one of these actors alone. The questions in of the ERA4Health Responsible Innovation Journey Guide concern the relationships between them — who sets the agenda, who is consulted, who carries the risk, who gains access — as much as the internal conduct of a project.

The new guide sets out a Responsible Innovation Journey for health research and innovation, organised by the maturity of a project rather than by administrative milestone. This guide encompasses these RRI themes in a health science setting:

- **Responsible Conduct of Research (RCR)** – as ethics in design and continuous oversight.
- **Sustainability and circularity** – environmental, social, economic and long-term responsibility.
- **Research security** –dual use and geopolitical risks, protection against misuse.
- **Social science and humanities (SSH) integration** – reflexive capacity, interdisciplinarity and societal insight
- **Equity, access and inclusive innovation** – who benefits, who is left out, and whether results will reach the people whose need is greatest
- **Openness, engagement and science literacy** – open science (OS), public engagement and an informed citizenry as conditions for trust and uptake.

In the guidelines for applicants, the listed questions and points provide overall ideas and advice but cannot give a recipe that all potential applicants may use. However, by using this journey guide and appropriately integrating the results of doing so, applicants and granted will have taken an important step toward more deeply engaging with and considering the tensions and meaningful societal benefits associated with health research and innovation. This guide is designed for selective use rather than cover-to-cover reading. **Start with the mindset** and phase that matches your current situation: Phase 1 for early project framing; Phase 2 for proposal development; Phase 3 before submission. Use Annex 1 for definitions and Annex 2 when more detailed support for proposal development is needed. For your ease of access, these are shown below. The full guide for all phases and supporting information is found here (link).

In the preproposal and full proposal templates, three sections/points refer to RRI and RCR and leave space for you to explain your approaches:

- General RRI and Societal Readiness (SR) approaches
- Involvement of stakeholders and the public
- RCR (in your journey and in your ethics self-assessment)
- OS approach

ANNEX I

Belgium

Country	Belgium
Funding organisation	Fund for Scientific Research-FNRS (F.R.S.- FNRS)
National contact person	Dr. Maxime Bonsir +32 2 504 9236 Joël Groeneveld +32 2 504 9270 international@frs-fnrs.be
Funding commitment	300.000 €
Anticipated number of fundable proposals	1
Maximum/ Minimum funding per grant awarded to a project partner	300 000 € for a total period of three years. If the project involves the recruitment of a PhD student, the project duration of the F.R.S.-FNRS sub-project could be up to four years (see PINT-MULTI Regulations for details)
Eligibility of partners	All eligibility rules and criteria can be found in the PINT-MULTI Regulations. It is **strongly advised** to contact the F.R.S.-FNRS prior to submission regarding the eligibility criteria. Please note that the F.R.S.-FNRS only funds Basic research (low Technology Readiness Level) carried out in a research institution from the "Fédération Wallonie-Bruxelles". The F.R.S.-FNRS will not fund industrial partners or any activity related to the private sector. Nevertheless, partners funded by the F.R.S.-FNRS can be in a consortium where there are also partners from the private sector. Clinical research is eligible for funding by the F.R.S.-FNRS under the condition that the funded research is oriented towards the understanding of fundamental mechanisms, excluding clinical trials with purely therapeutic or industrial goals.
Eligibility of costs, types and their caps	All eligibility rules and criteria can be found in the PINT-MULTI Regulations. https://www.frs-fnrs.be/docs/Reglement-et-documents/International/FRS-FNRS_PINT-Multi.pdf Please check the Practical guide on costs for any other questions. Please do not include overhead costs in the budget, as these are covered through a separate agreement between the FNRS and the host research institution in the event that the project is funded
Submission of the proposal at the national level	Applicants to F.R.S.-FNRS funding must provide basic administrative data by submitting an administrative application on e-space **within 5 working days after the general deadline of the ERA4Health call to be eligible**. Please select the "PINT-MULTI" funding instrument when creating the

	administrative application. Proposals invited to the second stage will be able to complete the pre-proposal form and provide information for the full proposal upon validation by the F.R.S.-FNRS.
Submission of other information at the national level	As described in the PINT-MULTI Regulations.
Submission of financial and scientific reports at the national level	Financial reporting must be submitted to the F.R.S.-FNRS. As described in the PINT-MULTI Regulations.
Further guidance	PINT-MULTI Regulations, e-space

Egypt

Country	Egypt
Funding organisation	Academy for Science and Research Technology (ASRT)
National contact person	**Asmaa Abdellah and Amr Radwan** **Email:** innov@sti.sci.eg; engasmaa2005@gmail.com; radwan.amro@gmail.com **Telephone:** +20 2 2792 0126 **Address:** 101 Kasr Al-Ainy Street, 6th Floor, Cairo 11516, Egypt
Funding commitment	**EUR 300,000**
Anticipated number of fundable proposals	3 (indicative, subject to the scientific ranking, national eligibility and available budget)
Maximum/ Minimum funding per grant awarded to a project partner	• Up to EUR 100,000 where the Egyptian participant(s) participate as partner(s). • Up to EUR 130,000 where an eligible Egyptian legal entity acts as the coordinator. Where more than one Egyptian partner participates, the applicable ceiling is shared among all ASRT-funded Egyptian partners.
Eligibility of partners	• Eligible applicants are Egyptian legal entities established in Egypt, including public or private universities, research institutes, university hospitals and other healthcare or research institutions, non-profit organisations, SMEs and enterprises, provided that they can perform the proposed work and sign a national grant/contract with ASRT. • Participation of a private for-profit entity must be duly justified. A commercial enterprise or other for-profit organisation may not act as the clinical study coordinator. • All central ERA4Health eligibility and clinical-study requirements apply. Each Egyptian partner must have the expertise and institutional capacity required for its role; an Egyptian coordinator and/or sponsor must demonstrate capacity for multi-country study oversight, ethics, regulatory compliance and Good Clinical Practice. • At the time of national contracting, the Egyptian PI may not hold more than two ongoing ASRT-funded projects as PI or coordinator.
Eligibility of costs, types and their caps	**Funding rates** • Universities, public research bodies and public hospitals: up to 100% of eligible costs, subject to the national ceilings above. • Other legal entities (e.g., non-profits, SMEs, enterprises) able to carry out the work and sign a national grant/contract with ASRT. Applicants of other legal forms can contact ASRT before submission to confirm the applicable funding rate and any national conditions. **General conditions** • Costs must be necessary, reasonable, directly related to the approved work plan, appropriately documented and not financed from another source. **Eligible cost categories** 1. Personnel: PI, researchers, clinicians, data managers, technical and support staff assigned to the project. Time records are required. Personnel costs are capped at 25% of the ASRT-requested contribution for each Egyptian applicant.

	2. Consumables and project materials: laboratory consumables, kits, study materials and small supplies required for the approved activities. 3. Other direct clinical-study costs essential to achieve the objectives, such as sample processing, storage and shipment; access to specialised facilities, databases and software; patient and public involvement; data curation and repositories; regulatory or ethics-related fees; study insurance; monitoring; data management; biostatistical support; publication and intellectual-property costs; and external services that are not core scientific tasks. Such costs must be specifically justified. 4. Equipment: eligible only where directly required for the study and fully justified in relation to the proposed activities. 5. Travel and subsistence: in accordance with the applicable rules of the Ministry of Higher Education and Scientific Research and the host institution; economy class only; travel must directly serve the work plan, including justified consortium and ERA4Health meetings. 6. Meetings and events: reasonable organisational costs for scientific meetings, workshops and consortium meetings directly linked to the study. 7. Patient and Public Involvement (PPI) and FAIR data-management costs: eligible where relevant, including patient or user engagement, data curation and use of appropriate repositories. 8. Indirect costs (overheads): 5% of eligible direct costs. **Not eligible or capped** • Activities primarily supporting teaching programmes, stand-alone website launches, or the design or development of original teaching tools are collectively capped at 15% of the Egyptian applicant's requested budget. Research communication and dissemination remain eligible where directly linked to the study. • Costs related to activities with a direct commercial purpose, and costs not necessary for the approved clinical study are not eligible.
Submission of the proposal at the national level	No separate national proposal is required at the pre-proposal or full-proposal stage. The joint proposal must be prepared in English and submitted by the coordinating investigator through the ERA4Health electronic submission system in accordance with the call text.
Submission of other information at the national level	No additional national documentation is required at the initial submission stage. During the national eligibility check and grant-preparation stage, ASRT may request supporting legal, administrative, financial, ethical and regulatory documentation.
Submission of financial and scientific reports at the national level	ASRT-funded partners must submit periodic and final scientific and financial reports in accordance with the national grant/contract and applicable ASRT policies, in addition to the reporting required by ERA4Health and the Joint Call Secretariat. Reports must document progress against the work plan, milestones and recruitment targets, where applicable, and include statements of expenditure and supporting records.
Further guidance	none

France

Country	France
Funding organisation	French Research Funding Agency (ANR)
National contact person	Sandra Sinnassamy/Martine Batoux Phone number: +33 8 11 42 80 00 /+33 1 73 54 81 40 ERA4HealthCall@anr.fr
Funding commitment	2 000 000 €
Anticipated number of fundable proposals	4-6
Maximum/ Minimum funding per grant awarded to a project partner	ANR funding will be limited to 250 000 € per French applicant. For a French Partner taking over the coordination of the project, the maximum budget can be increased up to 330 000 €. Minimum amount per partner: 15 000 €. If there are two French partners in one project, the maximum amount per project is 450 000 €.
Eligibility of partners	ANR may finance fundamental research, industrial research and experimental developments. ANR may fund research organisations and undertakings, as defined by the EC regulation on State aid for research, development and innovation (see the ANR Funding regulations at actual costs for further reference). Only research organisations that have their primary establishment in France may be funded. As for undertakings, ANR may fund those that have their real head office in an EU member State and an establishment (primary or secondary) in France. This list is not comprehensive and funding rates vary. Please fill the form related to economical activities to identify your funding rate and consult the "Règlement financier - aide à coûts réels" (https://anr.fr/fileadmin/documents/2025/ANR-RF-072025-cout-reel.pdf) for more details. Please note that companies in difficulty are excluded from ANR subventions (More details here: ANR-RF-Fiche-EED-2021.pdf). Partners, whether legal entities or natural persons, that are subject to applicable sanctions imposed by European Union bodies are excluded from this call. The ANR will declare ineligible any Partners requesting funding from it that are associated, within the submitted project, with Partners targeted by a sanctions measure. As of the date of publication, these exclusions concern in particular Partners from the following countries: Russia and Belarus, as well as Partners from the territories of Ukraine not under the control of the Ukrainian government. This list is non-exhaustive and may change in the event of new sanctions decided by the European Union. In keeping with the national "PPST" policy (scientific and technological potential protection), applicants to ANR should consult their local "FSD" (security and defence officer, where available) on their project before applying. Applications to ANR may be forwarded to the HFSD of the

	French Ministry of research and higher education for screening. A negative appraisal by the HFSD may cause ANR to reject the proposal.
Eligibility of costs, types and their caps	Standard ANR funding rules apply for eligible costs, unless stated otherwise in the Annex « *Modalités pour les partenaires sollicitant une aide de l'ANR* ». These rules are specified in ANR's "ANR Funding regulations" details ("at actual costs" version). An explanatory note regarding the eligible costs is also available at: https://anr.fr/fr/rf/fiche-couts/ Eligible costs (e.g.: personnel costs, costs of instruments and equipment, additional overheads and other operating expenses incurred directly as a result of the research project such as, for instance: travel costs) and funding rates vary based on the type of research and research partner (more info here). Please note that expenses related to permanent staff stipends are not eligible for the Beneficiaries "à coût marginal".
Submission of the proposal at the national level **NEW**	Not at the pre-proposal stage. At the full-proposal stage, applicants to ANR funding must provide administrative and financial data by submitting an administrative application on ANR's submission tool IRIS. **Applicants are strongly advised to first prepare and complete their budget in the ANR submission platform, and then report/forward to the coordinator the same figures in ERA4Health submission platform (PT-outline).** This approach will help ensure consistency between both submissions and reduce the risk of discrepancies or errors in the financial data. For more details, please refer to the dedicated ERA4Health 2027 call page on the ANR website: https://anr.fr
Submission of other information at the national level	At the granting stage, partners selected for funding by ANR may have to adjust and complete administrative and financial data provided on the ANR platform
Submission of financial and scientific reports at the national level	The ANR funded partners must communicate to ANR the required Scientific reports, Consortium Agreement, Data management plans according to the funding contract and as required to the project coordinator by ERA4Health. Administrative reporting documents (financial reports or certificate of closure, depending on the type of beneficiary, must be communicated to ANR according to the provisions of ANR Funding regulations ("at actual costs" version). If applicable, Declarations of Due Diligence for the financed projects (Nagoya Protocol) must also be transmitted to ANR in due time.
Further guidance	A project proposal cannot be similar, in whole or in part, to another proposal submitted for a call currently being evaluated and requested funds to ANR (all calls for proposals and evaluation stages considered) or already funded by ANR. Similarity between two projects is established when these projects (in whole or in part) describe identical main objectives or are the result of a simple adaptation.See Annex « *Modalités*

	pour les partenaires sollicitant une aide de l'ANR » for additional ANR rules available on the ANR website. The above-mentioned terms and conditions are only summarized translations of those entailed in the ANR Funding regulations and in the Annex. In case of inconsistencies, the terms of the ANR Funding regulations and the Annex shall prevail. Please consult these documents for more details.

Hungary

Country	Hungary
Funding organisation	National Research, Development and Innovation Office (NKFIH)
National contact person	Zsuzsanna Kürti National Research, Development and Innovation Office Budapest 1077, Kéthly Anna tér 1. ncp@nkfih.gov.hu
Funding commitment	200 000 EUR
Anticipated number of fundable proposals	**1-2 (The number of projects funded depends on the requested amount in the submitted applications.)**
Maximum/ Minimum funding per grant awarded to a project partner	200 000 EUR
Eligibility of partners	Institution of higher education, Other budgetary research institution, Other budgetary institution (outside education or research), Enterprise-based research organisation, Enterprise (non-research type), Non-profit research organisation, Other non-profit organisation (outside research), HUN-REN Hungarian Research Network. All eligibility rules and criteria can be found in the national call. **Please consult the national call for participation eligibility and funding intensity: Call for proposals to support Hungarian organisations successfully participating in the joint international calls for proposals of European Partnerships in Horizon**: https://nkfih.gov.hu/palyazoknak/nkfi-alap/horizont-europa-europai-partnersegek-magyar-szervezetek-tamogatasa-2024-121-he-partnerseg/palyazati-felhivas Applicants are advised to verify the applicable funding intensity and eligibility conditions in the relevant National Call.
Eligibility of costs, types and their caps	Please consult the Hungarian national call on the eligibility of specific cost categories: https://nkfih.gov.hu/palyazoknak/nkfi-alap/horizont-europa-europai-partnersegek-magyar-szervezetek-tamogatasa-2024-121-he-partnerseg/palyazati-felhivas
Submission of the proposal at the national level	Personnel (temporary, permanent), subcontracting, services, travel, consumables, equipment, coordination, communication and dissemination, overhead (20%), overhead for travel related activities (5%). Please consult the national call for cost eligibility. https://nkfih.gov.hu/palyazoknak/nkfi-alap/horizont-europa-europai-partnersegek-magyar-szervezetek-tamogatasa-2024-121-he-partnerseg/palyazati-felhivas
Submission of other information at the national level	The Hungarian partners of proposals recommended for funding have to submit an application for the national call after having been informed of the international funding decision. For details, please refer to the Guide for Applicants for the **2024-1.2.1-HE_PARTNERSÉG** national call :

	https://nkfih.gov.hu/palyazoknak/nkfi-alap/horizont-europa-europai-partnersegek-magyar-szervezetek-tamogatasa-2024-121-he-partnerseg/palyazati-felhivas
Submission of financial and scientific reports at the national level	The Guide for Applicants for the 2024-1.2.1-HE_PARTNERSÉG national call is applicable. **https://nkfih.gov.hu/palyazoknak/nkfi-alap/horizont-europa-europai-partnersegek-magyar-szervezetek-tamogatasa-2024-121-he-partnerseg/palyazati-felhivas**
Further guidance	The Guide for Applicants for **2024-1.2.1-HE_PARTNERSÉG** national call is applicable. https://nkfih.gov.hu/palyazoknak/nkfi-alap/horizont-europa-europai-partnersegek-magyar-szervezetek-tamogatasa-2024-121-he-partnerseg/palyazati-felhivas

Israel

Country	Israel		
Funding organisation	Ministry of Health (CSO-MOH)		
National contact person	Dr. Irit Allon	irit.allon@moh.health.gov.il	+972 (0)2 5082167
	Netta Koren	netta.koren@moh.health.gov.il	+972 (0) 545889393
Funding commitment	320,000 €		
Anticipated number of fundable proposals	Up to 2 Projects		
Maximum/ Minimum funding per grant awarded to a project partner	Up to 140,000 € Additional 20,000 € for coordination		
Eligibility of partners	Position in a university, research center or hospital. Research authority must approve position prior to submission.		
Eligibility of costs, types and their caps	Materials and consumables; Travel and hosting (up to 5%); No salaries for applicants; No heavy equipment, Institutional overhead 10%.		
Submission of the proposal at the national level	Prior to submission, researchers will submit to CSO-MOH an abstract approved by their research authority including budget distribution. No submission of abstract can result in declaration of the consortium as ineligible.		
Submission of other information at the national level	If the application involves human or animal experiments, bioethics approvals must be submitted with the application.		
Submission of financial and scientific reports at the national level	Required annually.		
Further guidance	Please see detailed instructions of application at the national level and reporting at https://www.gov.il/he/service/era-net-instructions-for-israeli-researchers		

Italy

Country	Italy
Funding organisation	Ministry of Health (IT MOH)
National contact person	Grazia Papagni int-dgric@sanita.it; g.papagni@sanita.it, Filomena Cichello f.cichello@sanita.it
Funding commitment	500.000 €
Anticipated number of fundable proposals	2
Maximum/ Minimum funding per grant awarded to a project partner	Maximum 400.000 € per project. In case two eligible partners (IRCCS) are involved in the Consortium, the total amount must be shared between them. No more than two partners may receive funding under the same project.
Eligibility of partners	Only IRCCS (Istituti di Ricovero e Cura a Carattere Scientifico) researchers are eligible to apply. Not eligible for funding: Universities, other research Institutes, companies. Addictional elegibility criteria: • A Principal Investigator (PI) cannot participate in more than one 2027 Joint Transnational Call (JTC) funded by the Italian Ministry of Health. If the PI is already the beneficiary of other active projects funded by the Italian Ministry of Health within European JTC schemes, the researcher is not allowed to submit a new application. • A PI holding an active IT-MoH grant may submit a proposal to a new JTC only if the ongoing project has been formally closed prior to the pre-proposal submission deadline. A project is deemed closed only upon submission and formal acceptance by the Italian Ministry of Health of both the final financial report and the final scientific report through the Workflow Research platform. If the ongoing project is expected to conclude within six months from the JTC pre-proposal deadline, the PI must submit a formal declaration stating that no request for project extension will be made. • These eligibility restrictions apply exclusively to individuals serving as Principal Investigators. Co-investigators, collaborators, and other project team members who are not designated as PIs are not subject to these limitations. • No more than two Italian PIs are eligible to apply for the same project.
Eligibility of costs, types and their caps	**Direct Costs:** • Personnel (only temporary contracts or permanent contracts for the number of hours dedicated to the project) Max. 60%. • Consumables/Supplies. • Equipment (only on leasing or rent). • Travel (Max. 30%). • Dissemination activities (Max. 1%). • Publication costs: Max. 2%; Open Access Max 5%. **Other direct costs such as:** • Patients' recruitment costs.

	• Animals/Model costs. • Coordination costs only for Coordinator **Indirect Costs:** Overhead (Max.10%, of direct costs). Other indirect costs are not eligible. Transfer of eligible funds abroad is not allowed. **Subcontracts (max 10%)**: they are allowed ONLY upon approval by Italian Ministry of Health presenting via Workflow research platform (ER communication code) a request together with the pre-eligibility check form, 20 working days before the pre-proposal submission deadline. Subcontracting cannot involve the core activities of the project. Italian PAOs can be funded as a sub-contractor of an IRCCS if they fulfil the eligibility criteria of the EC.
Submission of the proposal at the national level	Applicants are required to complete and submit a pre-eligibility check form to the Italian Ministry of Health using the Workflow Research platform (ER communication code), before submitting their pre-proposal to the Joint Call Secretariat (JCS). The completed form has to be submitted no later than 20 working days before the pre-proposal submission deadline. If subcontracting is envisaged, it must be explicitly requested and pre-approved by the Italian Ministry of Health as part of the eligibility clearance process. Such requests must be submitted alongside the pre-eligibility check form. Changes to the PI, the project acronym or budget declared in the pre-submission eligibility check are not permitted. The mandatory pre-eligibility check form and the GDPR Article 13 Information Notice can be downloaded at the following link: https://www.salute.gov.it/new/it/tema/sistema-ricerca-del-ssn-enti-e-finanziamenti/internazionalizzazione-della-ricerca-biomedica/ Applicants will receive written notifications of their eligibility status. After completion of the JTC peer review process and endorsement of the final (scientific) ranking list by the Call Steering Committee, the Italian Ministry of Health will contact the PIs of the awarded projects for the necessary follow-up actions.
Submission of other information at the national level	
Submission of financial and scientific reports at the national level	Submission of final scientific and financial reports at Italian Ministry of Health will be required.
Further guidance	Further information on the rules and guidelines of the Italian Ministry of Health can be found at https://www.salute.gov.it/new/it/tema/sistema-ricerca-del-ssn-enti-e-finanziamenti/internazionalizzazione-della-ricerca-biomedica/

Latvia

Country	Latvia
Funding organisation	Latvian Council of Science
National contact person	Uldis Berkis E-mail: Uldis.Berkis@lzp.gov.lv Tel.: +371-29472349
Funding commitment	600 000 EUR
Anticipated number of fundable proposals	2
Maximum/ Minimum funding per grant awarded to a project partner	300.000 Euros per partner, not exceeding 100.000 EUR per year per beneficiary Funding rates under Regulation EC 651/2014 shall be respected in case of state aid. Maximum 2 Latvian beneficiaries per proposal, they must be fully independent on legal, financial and personnel basis.
Eligibility of partners	Only the following **legal persons** are eligible: 1) Research institutions registered in the Latvian Registry of Scientific Institutions, e.g. - Research Institutes - Universities And must have the status of Research and knowledge dissemination organization (Regulation EC 651/2014) 2) Business enterprises entered into the Latvian Commercial registry as companies, assumed they are eligible to do the specific research and have specific capacity and resources to do the research in Latvia and have their main activity in Latvia. Limitations of EU legislation apply (Regulation 651/2014) together with financial reporting requirements, in this case it is state aid. Two previous statements with sworn auditor's approval should be provided and they must reflect the correspondence to the regulation as well as prove the evidence of previous scientific activity and presence of capacity. Enterprises not having closed two annual financial periods are not eligible. Latvia allows max 2 Latvian partners per proposal, they must be fully independent on legal, financial and personnel basis.
Eligibility of costs, types and their caps	• Personnel costs incl. taxes; • Consumables; • Subcontracts (up to 25% of direct costs), needs detailed justification, includes all external services, project core activities cannot be subcontracted; • Equipment (only depreciation costs during project directly attributable to project tasks); • Replaceable and fully consumable during project elements of equipment (e.g. electrodes); Travels (according to travel plan); Indirect costs (up to 25% of direct costs excluding subcontracting).

Submission of the proposal at the national level	Not during the application phase. The proposal shall be attached to the request for funding in case the proposal is selected for funding
Submission of other information at the national level	Applicants for State aid must send before the call deadline (both 1st and 2nd stages) to the e-mail address lzp@lzp.gov.lv, stating the acronym and the title of the project, applicant name and registration number in Latvia, the following document: a certification that the applying legal person does not correspond to the criteria laid down in laws and regulations to be subject to insolvency proceedings at the request of the creditor. It must be electronically signed by valid legal representative (s). Upon request applicants for State aid must provide all requested documents to evaluate the financial situation and financial viability. Undertakings in difficulty are not eligible for funding. (Regulation 651/2014) In case of State aid, the undertakings are assessed for eligibility at each of the application stages and at the conclusion and during execution of the contract with LCS for project funding. If the eligibility criteria are not fulfilled, project funding cannot be approved or continued.
Submission of financial and scientific reports at the national level	Annual or in some cases half-annual financial and scientific reporting is mandatory. Final audit according to the LCS regulations.
Further guidance	Support is provided according to Provisions Nr 259, 26.05.2015 of the Latvian Cabinet of Ministers (http://likumi.lv/ta/id/274671-atbalsta-pieskirsanas-kartiba-dalibaistarptautiskas-sadarbibas-programmas-petniecibas-un-tehnologiju-joma) These provisions should be respected without exceptions. The maximum rates should respect the Provisions. The requirements in the provisions to specific applicant groups must be respected. LCS cannot fund implementation support, nor training activities. LCS is not funding any activity beyond experimental development. LCS is funding only research. LCS funding can be operated only via a Latvian bank account. To receive funding by LCS, Consortium agreement duly signed should be presented. Application for the state aid must be submitted before the start of the project which is stated in the consortium agreement. Enterprises shall provide audited statements of 2 previous closed financial periods on request.

Lithuania

Country	Lithuania
Funding organisation	Lietuvos mokslo taryba (LMT) -Research Council of Lithuania
National contact person	Živilė Ruželė, Tel.: +37 067 614383 E-mail: zivile.ruzele@lmt.lt
Funding commitment	300 000 Eur
Anticipated number of fundable proposals	1-2
Maximum/ Minimum funding per grant awarded to a project partner	Within a single project proposal, the maximum funding can be up to EUR 150 000 – for a mere consortium partner; up to EUR 200 000 – for a coordinator or 2 eligible mere partners in a consortium; up to EUR 250 000 – for a coordinator and 1 eligible mere partner in a consortium
Eligibility of partners	Eligible for funding institutions are Lithuanian research and higher education institutions that are included in the Register of Education and Research institutions, public healthcare institutions, academy of science mentioned in the state Law on Science and Studies, other state public institutions such as National libraries, archives, museums. Beneficiary institution (grant holder) manages the state budget funds allocated to the project following the rules stated in the legal acts, as well as representing the project partners (if applicable 'project partner' means public or private legal entity that, together with the eligible institution, created the conditions for project implementation). Principal investigator (PI) must hold a PhD degree. The beneficiary institution is responsible for employing the Principal Investigator for the duration of the project. The PI's workload must be at least 20 hours per month, multiplied by the total number of months of the project's duration. Personnel costs must be calculated using the hourly rates approved by the Chairman of the Research Council of Lithuania. All other general rules for the competitive funding administered by the Research Council of Lithuania apply: https://www.e-tar.lt/portal/lt/legalAct/0a8bead0577611e9975f9c35aedfe438/asr
Eligibility of costs, types and their caps	Only costs generated during the lifetime of the project, related to project are eligible: staff, travel, consumables, subcon-tracts, contractual research, consultancy, equipment and instruments, dissemination of results, data handling and analysis, overheads (up to 20 % from direct costs).
Submission of the proposal at the national level	Submission of the proposal at the national level is not required at the application stage.
Submission of other information at the national level	Following a positive funding decision, the grant-signing institution and the Principal Investigator (PI) must complete and submit a national document (template available [at this link]) containing the following information: A more detailed planned budget Foreseen dissemination and communication activities Expected project outputs and contributions from the granted research team (e.g., scientific publications, patents, etc.)
Submission of financial and	Quarterly and yearly financial reports and two (2) scientific reports (mid-term and final) are required.

scientific reports at the national level	
Further guidance	For any information, please refer to the responsible contact person. All information about the call is published on LMT website under Calls webpage. General information for applicants submitting proposals to European Partnerships calls can be found here.

Norway

Country	Norway
Funding organisation	The Research Council of Norway (RCN)
National contact person	Cecilie A. Mathiesen + 47 456 90 357 Forskningsrådet Kontakt-Contact
Funding commitment	2 000 000 EUR Depending on the quality and number of eligible projects, available funding may be increased by up to 25 % to fund additional projects on the ranking list.
Anticipated number of fundable proposals	About 5
Maximum/ Minimum funding per grant awarded to a project partner	For a single partner role, the funding can be up to 380 000 EUR. If the Norwegian participant has a coordinator role, the funding can be up to 420.000 EUR. If the project has more than one Norwegian partner, the maximum total RCN funding is up to 450.000 EUR. For funded projects, the contractual budget will be in NOK using the exchange rate (European Central Bank) from the pre-proposal deadline.
Eligibility of partners	Norwegian universities, university colleges, hospitals, research institutes, public sector, user organisations, NGOs, SME and other private industry. The Research Council cannot award support to an enterprise that is defined as an "undertaking in difficulty" under the state aid rules (see the "Definition of 'undertaking in difficulty" on our website). "Enkeltpersonforetak", that is Norwegian companies with sole proprietorship, cannot participate in this call. Technology Transfer Offices (TTOs) are not eligible partners in this call.
Eligibility of costs, types and their caps	Pa Payroll expenses, procurement of R&D services, consumables, network measures. The RCN research project budget rules should be followed, see Budget. PhD fellowships are not recommended within the national funding due to the project length limitation of three years. For postdoctoral fellowships, duration of the support is limited to a minimum and maximum of three years. The overhead costs to be included in the costs for personnel. SME or other industrial partner is funded with up to 50 % of their eligible project costs and in line with the State aid rules, see State aid.
Submission of the proposal at the national level	If the proposal is granted, information about national project registration will be given.

Submission of other information at the national level	On request in case of a positive funding recommendation.
Submission of financial and scientific reports at the national level	On request in case of a positive funding recommendation.
Further guidance	Requirements and guidelines for registration and disclosure of medical and health-related studies involving human participants must be followed, please see Requirements and guidelines for registration and disclosure of medical and health-related studies involving human participants

Poland

Country	Poland
Funding organisation	National Centre for Research and Development (NCBR)
National contact person	Marcin Chmielewski era4health@ncbr.gov.pl +48 571 226 666
Funding commitment	1 250 000 €
Anticipated number of fundable proposals	1 - 3
Maximum/ Minimum funding per grant awarded to a project partner	Maximum 400 000 € per project, regardless of the number of Polish partners in the project consortium
Eligibility of partners	Following entities are eligible to apply: • Enterprises[13] - Micro, Small, Medium and Large, • Research organisations[14], • Groups of entities composed of at least two enterprises, • Groups of entities composed of at least one research organisation and at least one enterprise, • Group of entities composed of at least two research organisations. Entities must be established under Polish law either as a legal person[15] or as a sole trader[16] and must conduct business, R&D activity or other activity on the territory of the Republic of Poland, confirmed by an entry into the relevant register[17]. For a group of entities to participate as an Applicant in the call, it must formally exist on the date the pre-proposal is submitted. This existence must be evidenced by an agreement made by the members - at least conditionally - to create the group of entities (consortium). Please note that a group comprising two partners from Poland counts towards the limit on the number of participants from the same country (further details can be found in the call text). For enterprises it is strongly advised to state in the pre-proposal application form the KRS number of the enterprise and the size of the enterprise (micro/small, medium, large).

[13]as defined in Annex I to Commission Regulation (EU) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in application of Articles 107 and 108 of the Treaty (hereinafter referred to as "Commission Regulation (EU) No 651/2014");
[14]Research organisation - an entity defined in Article 2(83) of Commission Regulation (EU) No 651/2014, and in Article 37(1) of the Act of 30 April 2010 on the National Centre for Research and Development (Polish Journal of Laws 2024, item 1170 as amended), in conjunction with Article 7(1)(1, 2, 4, 5, 6, 6a, 6b, 6c, 8) Act of 20 July 2018 of the Law on Higher Education and Science (Polish Journal of Laws 2024, item 1571 as amended);
[15]Legal person - an entity other than a natural person that has the legal capacity to hold and to exercise legal rights and obligations within a certain legal system, in particular to enter into contracts, sue and be sued.
[16] Sole trader (sole proprietor, self-employed person) – a natural person conducting economic activity in their own name and on their own account, including as a partner in a civil law partnership (spółka cywilna).
[17]If applicable. Does not apply to legal persons that are not obliged to register in a relevant Polish official register according to Polish law (e.g. KRS, CEIDG).

Eligibility of costs, types and their caps

The eligible costs shall be the following:

- For research organisations:
  1. **personnel costs**
  2. **consumables**
  3. **equipment**
  4. **travel**
  5. **other direct costs**
  6. **subcontracting** – used exclusively for the research activity; this cost category shall not exceed 70% of all eligible costs of a project
  7. **additional overheads** – incurred indirectly as a result of the research project. These costs are counted by multiplying direct costs (excluding subcontracting [6]) by 25%. It means 7 = (1+2+3+4+5)*25%.

- For enterprises:
  1. **personnel costs**
  2. **equipment**
  3. **other direct costs –** please refer to cost eligibility guide (przewodnik kwalifikowalności kosztów) for more details
  4. **subcontracting** – used exclusively for the research activity; this cost category shall not exceed 70% of all eligible costs of a project
  5. **additional overheads** – incurred indirectly as a result of the research project. These costs are counted by multiplying direct costs by 20%. It means 5=(1+2+3+4)*20%.

For more details on eligible costs, applicants are advised to check cost eligibility guide (**przewodnik kwalifikowalności kosztów**) in the call announcement on NCBR webpage.

	Large Enterprises	**Medium Enterprises**	**Small Enterprises**	**Research organisations**
Fundamental/Basic Research	Not eligible	Not eligible	Not eligible	Not eligible
Industrial/Applied Research	Up to 50 + 5/15/25 (max 75 %)	Up to 50 + 10 + 5/15/25 (max 80 %)	Up to 50 + 20 + 5/15/25 (max 80 %)	Up to 100%
Experimental Development	Up to 25 + 5/15/25 (max 50 %)	Up to 25 + 10 + 5/15/25 (max 60 %)	Up to 25 + 20 + 5/15/25 (max 70 %)	Up to 100 %

In any case only **Industrial/Applied Research** and **Experimental Development** are eligible for funding. Fundamental/Basic research is not eligible for funding. Other activities (e.g. coordination, dissemination, management) must not be included into separate tasks.

Funding quotas for Polish participants may reach up to 100% for universities and research organisations. For enterprises, the quota will be determined on a case-by-case basis, taking into account company size and the type of research and development activity, pursuant to Section 2 of the Regulation of the Minister of Science and Higher Education of 19 August 2020 on granting state aid by the National Centre for Research and Development.

	For entrepreneurs independently undertaking projects at the national level (meaning there is no Polish group of entities or Polish group of enterprises), there is no possibility of increasing the intensity of state aid by 15 percentage points for industrial research and experimental development based on the condition of effective cooperation between entrepreneurs or between entrepreneurs and research organisations.
Submission of the proposal at the national level	Participants from Poland will be informed and invited to submit a national application form (NAF) once the international evaluation and the ranking list have been established. Only projects recommended for funding will be asked to submit a NAF. **If more than one Polish entity participates in the project, the national application form must be submitted jointly by a consortium (group of entities) comprising Polish entities only.** In justified cases, the composition of group of Polish entities may be changed before the funding decision is issued by NCBR. Any changes must meet the call's eligibility criteria and be approved in advance by the international project consortium, the call secretariat, NCBR, and any other funding institutions involved. Changes must also respect the principle of equal treatment of applicants.
Submission of other information at the national level	All entities invited to submit national application form (NAF) are obliged to use European Central Bank's exchange rate in force on the day the call is opened.
Submission of financial and scientific reports at the national level	Annual scientific reports are obligatory.
Further guidance	Sample documents are available at: https://www.gov.pl/web/ncbr/wniosek-krajowy-w-lsi We encourage you to learn about and use our **PartFinder** (Partner Search Tool), which allows you to match science and industry entities from around the World with each other. The search engine is available at: https://partfinder.ncbr.gov.pl/ <u>Relevant documents</u> All proposals must be aligned with national regulations, inter alia: • The Act of 20 July 2018 - Law on Higher Education and Science; • The Act of 30 April 2010 on the National Centre for Research and Development; • The Regulation of the Minister of Science and Higher Education of 19 August 2020 on granting state aid by the National Centre for Research and Development, which is in line with the Commission Regulation (EU) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in application of Articles 107 and 108 of the Treaty (General Block Exemption Regulation); • The Regulation of the Minister of Science and Higher Education of 17 September 2010 on the detailed mode of performance of tasks of the National Centre for Research and Development. In light of the European Commission's ongoing work on a regulation intended to replace Regulation (EU) No 651/2014, the National Centre for Research and

	Development (NCBR) informs that the conditions governing the provision of support set out in this documentation may be amended following the entry into force of the new European Commission regulation. NCBR may enter into a project contract provided that the participating entity: 1) is not excluded from applying for funding on the basis of: a. Article 207(4) of Act of 27 August 2009 on Public Finance (Polish Journal of Laws 2025, item 1483 as amended); b. Article 12(1)(1) of the Act of 15 June 2012 on the consequences of entrusting work to foreigners staying illegally in the territory of the Republic of Poland (Polish Journal of Laws 2025, item 1567 as amended); c. Article 9(1)(2a) of the Act of 28 October 2002 on the liability of collective entities for acts prohibited under penalty (Polish Journal of Laws 2024, item 1822 as amended); 2) is not an entity subject to an obligation to repay aid because the European Commission has declared such aid unlawful and incompatible with the internal market, 3) is not in arrears with payments of public dues or with social security and health insurance contributions, 4) is not an undertaking in difficulty[18] within the meaning of EU state aid rules and is not under receivership, 5) is not subject to exclusion from applying for funding due to sanctions.

[18] the definition of an undertaking in difficulty is set out in Article 2(18) of Regulation (EU) No 651/2014.

Romania

Country	Romania
Funding organisation	Executive Agency for Higher Education, Research, Development and Innovation Funding
National contact person	Mihaela Manole E-mail: mihaela.manole@uefiscdi.ro Phone: +40 21 302 38 63 Nicoleta Dumitrache E-mail: nicoleta.dumitrache@uefiscdi.ro Phone: +40 21 302 38 86
Funding commitment	1.000.000 euro
Anticipated number of fundable proposals	4-5
Maximum/ Minimum funding per grant awarded to a project partner	Funding rates vary in accordance with state aid legislation. For more information : https://uefiscdi.gov.ro/parteneriate-si-misiuni-europene https://uefiscdi.ro/pachet-de-informatii-suprogramul-3-2-orizont-2020 250.000 euro for all Romanian partners in case a Romanian institution is the Coordinator; 200.000 for all Romanian partners in case a Romanian institution is not the Coordinator.
Eligibility of partners	Eligible entities for funding are universities, public institutions, R&D national institutions, joint-stock companies, SME's and Large companies, NGOs (associations, foundations, etc.), others. Funding rates vary in accordance with state aid legislation https://uefiscdi.gov.ro/pncdi-iv-program-8
Eligibility of costs, types and their caps	a. Staff costs; b. Logistics expenses - Capital expenditure; - Expenditure on stocks - supplies and inventory items; - Expenditure on services performed by third parties cannot exceed 25 % of the funding from the public budget. The subcontracted parts should not be core/substantial parts of the project work; c. Travel expenses; d. Overhead (indirect costs) is calculated as a percentage of direct costs: staff costs, logistics costs (excluding capital costs and cost for subcontracting) and travel expenses. Indirect costs will not exceed 25 % of direct costs.
Submission of the proposal at the national level	NO
Submission of other information at the national level	NO
Submission of financial and	NO

<table>
<tr><td>scientific reports at the national level</td><td></td></tr>
<tr><td>Further guidance</td><td>Maximum funding percentages:
<table>
<tr><th>Type of research</th><th>Large Enterprises</th><th>Medium Enterprises</th><th>Small Enterprises</th><th>Universities and research organisations</th></tr>
<tr><td>Fundamental/Basic Research</td><td>100%</td><td>100%</td><td>100%</td><td>100%</td></tr>
<tr><td>Industrial/Applied Research</td><td>Up to 50+15 (max 65%)</td><td>Up to 60+15 (max 75%)</td><td>Up to 70+10 (max 85%)</td><td>100%</td></tr>
<tr><td>Experimental development</td><td>Up to 25+15 (max 40%)</td><td>Up to 35+15 (max 50%)</td><td>Up to 40+15 (max 65%)</td><td>100%</td></tr>
</table></td></tr>
</table>

Slovakia

Country	Slovakia
Funding organisation	Slovak Academy of Sciences (SAS)
National contact person	Katarina Bibova katarina.bibova@urad.sav.sk
Funding commitment	240.000€
Anticipated number of fundable proposals	2
Maximum/ Minimum funding per grant awarded to a project partner	Up to 120.000€ per project
Eligibility of partners	Only research Institutes of the Slovak Academy of Sciences are eligible organisations for funding by SAS (up to 100%). 1. The Slovak principal investigator must have a job contract for more than 50% working hours in the SAS organization for which the project proposal or participation in the project proposal is submitted. 2. Other researchers, except for doctoral students, must have a working relationship with the SAS organization. 3. Each researcher of the Slovak partner research team of a project consortium (other than the Slovak Principal Investigator) must have a job contract with or a fellowship with the Slovak Principal Investigator, lasting until the end of the project or beyond.
Eligibility of costs, types and their caps	Total eligible costs = Direct + Indirect costs (DC + IC) Direct costs (DC): Personnel (max. 15% of DC), Consumables and Travel costs Indirect costs (IC, Overheads): max. 20 % of DC. Limitations and specifications are available: (https://oms.sav.sk/wp-content/uploads/Financne-pravidla-na-udelovanie-grantov-SAV-na-medzinarodne-vyskumne-projekty-platne-na-vyzvy-zverejnene-od-1.12.2023.pdf)
Submission of the proposal at the national level	Submission of the proposal at the national level will be required once the international evaluation has taken place and the ranking list has been endorsed by the Joint Call Steering Committee (CSC). The Slovak partner will be informed about recommendation for funding by the project consortium coordinator and invited by SAS to submit the national proposal form (MVTS form). The Presidium of SAS makes the final decision concerning the approval of funding (according to internal rules of SAS).
Submission of other information at the national level	no
Submission of financial and scientific reports at the national level	Annual financial reporting

Further guidance	

Country	Slovakia
Funding organisation	Centrum vedecko-technických informácií Slovenskej republiky
National contact person	1. Contact: Marek Babušiak, PhD., European Partnerships Coordinator Email: marek.babusiak@cvtisr.sk, tel.: 00421 948 855 449 2. Contact: Libuša Ďaďová, European Partnerships Coordinator, Email: libusa.dadova@cvtisr.sk, tel.: 00 421 915 808 814
Funding commitment	500 000 EUR
Anticipated number of fundable proposals	1-3
Maximum/ Minimum funding per grant awarded to a project partner	The maximum funding amount is 300 000 EUR per Slovak partner, or 400 000 EUR if a Slovak partner acts as the project coordinator or if there are two Slovak partners participating in a single project. These amounts may be further increased by up to 15 000 EUR if a Slovak partner submits a patent, trademark, or design application, and/or publishes project results in an internationally indexed (peer-reviewed) scientific journal (e.g., WoS/Scopus). The minimum funding amount per Slovak project partner is 100 00 EUR.
Eligibility of partners	Legal entities established in the Slovak Republic, such as public or private research and academic institutions, higher education institutions, SMEs, public sector entities, and other relevant organizations actively involved in research, development, and innovation. • Research institutions (e.g. the Slovak Academy of Sciences and its institutes) • Academic sector (e.g. universities and higher education institutions) • Non-governmental non-profit organizations • Cluster organizations • Private sector entities (entrepreneurial/business sector) Public administration bodies, including local and regional government authorities, are eligible to participate; however, they are not eligible to receive funding and therefore cannot have a budget allocated to them.
Eligibility of costs, types and their caps	Only direct costs that are essential to the project implementation and are directly related to its activities and timeline are eligible. No indirect costs/overheads will be funded. All costs must be fully utilized and accounted for by the end of 2029. Eligible costs: • Personnel costs (salaries of researchers, technicians and other support staff employed by the beneficiary, to the extent that they are directly involved in the project; • Costs of instruments and equipment;

	• Costs for contract research, technical knowledge and patents purchased or licensed from external sources under market conditions, as well as costs for consultancy and equivalent services used exclusively for the project. General eligibility rule: All expenditures incurred by Slovak project participants must comply with: • Programme Slovakia, specifically Priority 1P1 Science, Research and Innovation, Specific objective RSO1.1: Development and enhancement of research and innovation capacities and the uptake of advanced technologies, Measure 1.1.3: Support for international cooperation in the field of research, development and innovation • The provisions of the State Aid Scheme to Support Partnerships in the Field of Research, Development and Innovation under the Programme Slovakia; • Strategy for Financing the ERDF, ESF+, CF, FST, and ENRAF 2021–2027. • Slovak applicants are advised to thoroughly familiarize themselves with the Guide for Applicants in European Co-funded Partnerships and Guide to Eligibility of Expenses under the Programme Slovakia, as the planned co-financing will be provided through this programme. It is further recommended that at least 30% of the Slovak applicant's total budget be dedicated to the actual performance of research activities.
Submission of the proposal at the national level	Submission of pre-proposal and full proposal to the ERA4Health JTC10 Call Secretariat only.
Submission of other information at the national level	Following the receipt of the formal international funding recommendation, applicants will be required to submit a separate application for national funding via the national submission platform. This serves as the final formal step, with the official funding decision issued by CVTI SR once the project has been successfully recommended by the Partnership.
Submission of financial and scientific reports at the national level	Yes, yearly.
Further guidance	The proposed research activities must be carried out in Slovakia, and their results must be applicable and utilized within the Slovak Republic's environment. The proposed project activities must be in line with the priorities defined in Programme Slovakia 2021-2027, Research and Innovation Strategy for Smart Specialisation of the Slovak Republic 2021-2027 (SK RIS3 2021+), State Aid Scheme to Support Partnerships in the Field of Research, Development and Innovation under the Programme Slovakia.

	All Slovak entities must have their contractual financial matters settled with CVTI SR by the end of 2029. All Slovak applicants are strongly advised to contact the CVTI SR's contact points before submitting their proposals. No change of the applicant institution is allowed between the stages. The information given in the pre-proposal is binding and no major changes regarding the proposal's content or objectives are allowed between the pre-proposals and full proposals (if invited to stage 2) including the proposed budget. However, a limited number of minor administrative changes including small budget reshuffles may be allowed. Any modification must ensure that the total funding requested in the full proposal does not exceed the amount declared in the pre-proposal stage. Useful links: Programme Slovakia SK RIS3 2021+ Strategy for Financing the ERDF, ESF+, CF, FST, and ENRAF 2021–2027 State Aid Scheme to Support Partnerships in the Field of Research, Development and Innovation under the Programme Slovakia

Spain

<table>
<tr><td>Country</td><td>Spain</td></tr>
<tr><td>Funding organisation</td><td>Agencia Estatal de Investigación</td></tr>
<tr><td>National contact person</td><td>Ana Revilla

Era4Health@aei.gob.es</td></tr>
<tr><td>Funding commitment</td><td>800.000 €</td></tr>
<tr><td>Anticipated number of fundable proposals</td><td>4-5</td></tr>
<tr><td>Maximum/ Minimum funding per grant awarded to a project partner</td><td>The following funding limits for a three-year project are considered eligibility criteria. Proposals not respecting these limits could be declared ineligible.

Two partners per project asking to the AEI are allowed only if one of them is the coordinator of the international proposal. The budget distribution in this case should be balanced.

<table>
<tr><th>Maximum funding per project</th><th>CD (€)*</th><th>CI (25%) (€)*</th><th>TOTAL (€)*</th></tr>
<tr><td>One AEI applicant (partner)</td><td>140.000</td><td>35.000</td><td>175.000</td></tr>
<tr><td>One AEI applicant – (coordinator)</td><td>220.000</td><td>55.000</td><td>275.000</td></tr>
<tr><td>One coordinator and one applicant- (balanced budgets)</td><td>260.000</td><td>65.000</td><td>325.000</td></tr>
<tr><td>Additional funding for substantial experimental tasks (per project)</td><td>30.000</td><td>7.500</td><td>37.500</td></tr>
</table>
* The direct costs must be rounded to the thousands in the application.
Indirect costs are 25% of direct costs requested.

Only excellent proposals with exclusively RDI activities will be funded by the AEI. Entire communication work packages, without research associated, are not eligible costs for AEI.

The final funding will take into account the transnational evaluation of the collaborative proposal, the scientific quality of the Spanish group, the added value of the international collaboration and the financial resources available.</td></tr>
<tr><td>Eligibility of partners</td><td>Eligibility for organizations (please read carefully)

The AEI will fund non-profit research organizations (such as universities, research centres, technological centres and other private non-profit institutions performing RDI activities in Spain). They must have been previously beneficiaries of any of the AEI calls, and they must ensure contractual relationship with the Principal Investigator (PI) during the whole duration of the project.

Be aware that applicants from the Accredited Health Research Institutes (IIS), hospitals, primary health care or public health administration of the</td></tr>
</table>

	Spanish National Health System (SNS) and CIBER must apply for funding to the Instituto de Salud Carlos III (ISCIII), also participating in this call. After the evaluation process and based on their budgetary availability and requested funding of selected projects, AEI and ISCIII reserve the right to exchange applicants to each other to optimize the available funds, provided the respective eligibility rules are met. IMPORTANT: Spanish legal entities which are part of mixed centres will be considered as a unique beneficiary, and thus the maximum funding should not exceed the limits per proposal established above. Although not fundable by the AEI, the private sector is encouraged to participate in consortia with Spanish academic groups, using their own funds or applying to national or regional calls by CDTI or regional innovation agencies. This is especially encouraged when there are for profit companies from other countries in the consortium or for projects coordinated by Spanish PIs. **Eligibility criteria for PIs** PIs must be eligible according to the PCI general requirements 4Sep26 of the corresponding PCI call (read PCI2026_1 call as an example) and read carefully the "General Conditions Trans Calls 2026" in Oportunidades de Colaboración
Eligibility of costs, types and their caps	○ Please, **consult "*Artículo 8. Conceptos financiables*"**, especially paragraph **a) Costes de Personal**, in PCI2026_1 call resolution as a reference, since eligible costs will be similar. ○ Contracts for supporting personnel (gross remuneration and social security contributions) related to the implementation of the funded project are eligible costs. The contract must specify the percentage of the hired person's time dedicated to the project. The costs of permanent staff linked to the beneficiary entity or members of the research team will not be considered eligible costs. ○ Direct costs such as current costs, disposable materials, travelling expenses, coordination costs, and other costs that can be justified as necessary to carry out the proposed activities are eligible. ○ Indirect costs (overheads) are eligible costs (25% of total direct costs, including subcontracting). ○ Subcontracting should not exceed 25% of total requested budget. ○ Clinical trials are eligible up to phase 1, with a maximum of 50% of the total budget.
Non-Eligible Topics	○ Proposals related to **neuroscience are not eligible** and will not be considered for funding.

Submission of the proposal at the national level **VERY IMPORTANT!**	**Funding Programme:** The framework for this funding action is the "Plan Estatal de Investigación Científica, Técnica e Innovación 2024-2027". On a national level, the call will be managed by the "Subdirección de Programas Horizontales e Internacionalización" of the AEI. **Instrument for funding** The instrument for funding the Spanish groups is the call for "Proyectos de Colaboración Internacional (PCI)". Please, read carefully PCI2026_1 call resolution as an example. **Submission of the pre and full proposal at the national level:** PIs and beneficiaries are strongly encouraged to check eligibility before submitting a pre-proposal, since no changes will be accepted afterwords. No PI or beneficiary changes will be accepted between pre and full proposal as well as during the national call phase. 1) **Within one week after the pre-proposal submission** in the partnership website, the Spanish PI must ALSO submit a copy of the international joint pre-proposal at the AEI application website. The Spanish **PI** and the "**Representante Legal**" of her/his institution must duly **sign the application electronically. Failure to provide both required signatures will result in the pre-proposal being declared ineligible and excluded from the evaluation process.** 2) The "**Declaración Responsable**"***** document can be downloaded from Oportunidades de Colaboración website and must be uploaded through the AEI application website. This document is **mandatory** and constitutes an essential requirement for the proper processing of the application. Applicants should include both the PI's full name (with both surnames, if applicable) and the **full legal name of their institution** as it is stated in SISEN – Sistema de registro de Entidades.
Submission of financial and scientific reports at the national level	Financial and scientific reports are required as indicated in the national PCI2026_1 call resolution since will be similar.
Further guidance	**Acknowledgement:** Any publication or dissemination activity resulting from the granted projects must acknowledge funding by the "Agencia Estatal de Investigación" according to AEI's web guidelines. Beneficiaries are obliged by these requirements and those of the international call. **Data Protection:**

	By submitting a grant application, the applicants consent to communication of the data contained in the application to other public administrations, with the aim of further processing of the data for historical, statistical or scientific purposes, within the framework of the Organic Law 3/2018, of December 5, on Personal Data.

Country	SPAIN
Funding organisation	Regional Ministry of Presidency, Healthcare and Emergencies of Andalusia (CPSEJA)
National contact person	Alicia Milano Curto E-mail: ep.fps@juntadeandalucia.es Tel: +34 955 04 04 50
Funding commitment	250.000 €
Anticipated number of fundable proposals	1-2
Maximum/ Minimum funding per grant awarded to a project partner	125.000€, 250.000 € if coordinator (including 21% indirect costs)
Eligibility of partners	Eligibility criteria established in Orden de 10 de agosto de 2023 • Eligible organisation must be Andalusian Non-profit entities registered as Agents of the Andalusian Knowledge System (Registro de Agentes Andaluces del Conocimiento) with research and innovation activity in Biomedicine and Health Sciences, ie: Research managing foundations of the Andalusian Public Health System. • https://juntadeandalucia.es/boja/2023/157/4Principal Investigators must be linked through a civil servant, statutory or labour relationship with the applicant or performing centre. For Health Research Institutes (Institutos de Investigación Sanitaria, IIS), the link may be with any of the public or private law entities that are part of the IIS provided that the entity meets all the specific requirements determined in each action, and, in any case, be personnel assigned to the IIS. • More than one partner from Andalusia may participate in the same project • A PI can only participate in one application per call. • For receiving regional funding, the final funding decision issued by the corresponding program's decision-making body must be accredited.
Eligibility of costs, types and their caps	A) **Goods and services**: consumables, bibliographic material, equipment rentals, software licenses and external services. B) **Personnel costs**: specifically hired for the project, including salaries, employer Social Security contributions, legally established compensation and other duly justified expenses derived. C) **Travel, accommodation and subsistence** according to the maximum amounts of compensation for service established in Decree 54/1989, of March 21, on compensation for service of the Junta de Andalucía, exclusively for people who are part of the research group or hired under the funded project. Exceptionally, any expense outside these amounts, or for people other than those listed before, must be authorised by the granting body.

	D) **Registration fees for congresses or conferences** for the presentation and dissemination of the results. Publication costs E) **Other expenses** duly justified and necessary for carrying out the project. F) **Indirect costs** 21% g) **Subcontracting costs**: cannot exceed 50% of the funding and need prior authorization from the granting body. Nor Scientific aspects nor the management of the project should be subcontracted. The following are not considered eligible expenses • Equipment or Equipment repair and maintenance • Items or amounts that, after analysis, are not considered justified • Amounts paid to persons participating in the project, except for expenses necessary for special attention to patients that involve compensation for their participation in the project not derived from an employment relationship. The sum of the funding or income received for the same purpose may in no case exceed the cost of the funded activity.
Submission of the proposal at the national level	No
Submission of other information at the national level	Additionally, for projects involving invasive procedures on human beings, their biological material and/or clinical data, a favourable report or a document accrediting the request for its evaluation by the Biomedical Research Ethics Committee must be provided. The documents to be provided are detailed in section 14 of the Orden de 10 de agosto de 2023.
Submission of financial and scientific reports at the national level	Beneficiaries must submit financial and scientific reports to Consejería de Salud y Consumo de la Junta de Andalucía (please see section 22.b) 3º and 25.f) 1º Orden de 10 de agosto de 2023)
Further guidance	The projects must respect the fundamental principles established in national and international declarations, protocols and conventions on research ethics, as well as respect the requirements established in national and regional legislation in the field of biomedical research, development and innovation, personal data protection and bioethics. When the results are not susceptible to protection of industrial or intellectual property rights, the scientific publications resulting from the funding granted must be made available in open access, in accordance with article 37 of Law 14/2011, of June 1.

Country	SPAIN
Funding organisation	SEKUENS – FICYT
National contact person	María González – maria.gonzalez@ficyt.es Ana Elena Fernández – anae@sekuens.es
Funding commitment	150.000 € *The indicative call budget could be increased by the same amount, provided that surplus funds are available from other SEKUENS calls for similar purposes when the decision is made.*
Anticipated number of fundable proposals	1-2
Maximum/ Minimum funding per grant awarded to a project partner	Maximum: €150.000 per partner and per project Maximum project duration: 36 months **Funding rates: 100%**
Eligibility of partners	**Non-profit entities, not engaged in economic activity,** with research and innovation activity in **Biomedicine and Health Sciences**, such as: • University of Oviedo • Hospitals and primary health care centers of the Asturias Health System • Accredited Health Research Institutes located in Asturias, or the foundation in charge of managing the research of these Institutes • Public or Private Research and Technology Organisations located in Asturias
Eligibility of costs, types and their caps	**Eligible costs include:** Costs must be directly related to the project: G) Personnel costs: New researchers and/or technicians hired specifically for the project Salaries, employer Social Security contributions, legally established compensation and other duly justified expenses. H) Materials and supplies I) Contractual research, knowledge, patents and consultancy services. Subcontracting costs up to 50% of the budget. J) Other direct costs: Duly justified and necessary for carrying out the project, such as: a. Auditing costs b. Travel, accommodation and subsistence Exclusively for members of the research group or project-hired staff. According to applicable regional regulations up to 8.000€ c. Registration fees for congresses or conferences related to the presentation and dissemination of project results

	Indirect costs: Up to 15% of eligible personnel costs **Note:** Equipment costs are **not eligible** under this call. **Minimum project eligible budget**: 100.000€; Recommended: 125.000€
Submission of the proposal at the national level	Applicants are encouraged to contact SEKUENS-FICYT prior to submission in order to receive instructions for the submission at the regional level.
Submission of other information at the national level	Applicants will be required to submmit preliminary information in advanced to SEKUENS-FICYT in order to verify eligibility at all the stages of the procedure.
Submission of financial and scientific reports at the national level	Beneficiaries will be required to submit final financial and scientific reports to SEKUENS-FICYT at the regional level.
Further guidance	Activities must fall under industrial/applied research or experimental development (TRL 3–8) Project activities cannot start before submission of the regional application The projects granted by SEKUENS must be aligned with at least one research area of those described in the **Smart Specialization Strategy of Asturias (S3),** particularly within the domains of **Active and Healthy Ageing and Sustainable Agro-Food Systems.** These areas include priorities such as the promotion of population health, the development of personalized nutrition strategies, and the prevention of chronic diseases like obesity. More information is available at: https://www.idepa.es/innovacion/s3-asturias/s3-asturias-2021-2027 **Applicants are limited to submitting 1 proposal per principal investigator.**

Country	Spain
Funding organisation	Institute of Health Carlos III (Instituto de Salud Carlos III- ISCIII)
National contact person	**Ana García Sacristán** anagarcia@isciii.es
Funding commitment	National programme: The Strategic Action in Health (Strategic Lines of Health Research 2024–2027, hereinafter **AES 2027**) **600.000 €**
Anticipated number of fundable proposals	2-3
Maximum/ Minimum funding per grant awarded to a project partner	**Maximum funding from ISCIII per awarded Spanish project:** If a Spanish Partner requesting funding to the ISCIII **IS NOT** the Coordinator of the transnational project: • **200.000 €** (overheads included), if there is only one Spanish Partner requesting funding to the ISCIII in the proposal. If a Spanish Partner requesting funding to the ISCIII **IS** the Coordinator of the transnational project: • **275.000 €** (overheads included), if there is only one Spanish Partner in the proposal, acting as a coordinator. Overheads according to AES 2027: 25% **Projects' duration**: from 24 months to 36 months The level of funding will take into account the evaluation of the collaborative proposal, the scientific quality of the Spanish group, the added value of the international collaboration, the participation of the primary health care and the financial resources available.
Eligibility of partners	A maximum of one partner requesting funding from ISCIII may participate in the same project proposal. **ELIGIBLE INSTITUTIONS:** • **Accredited Health Research Institutes (Institutos de Investigación Sanitaria acreditados, IIS).** Accredited according to the RD 279/2016 (These institutions may manage research via a foundation regulated according to the Spanish Act 50/ 2002, of December 26th). See the list of IIS in this **link**. • Hospitals, primary health care or public health administration of the Spanish **National Health System (SNS).** These institutions may manage research via a foundation regulated in accordance to the Spanish Act 50/2002, of December 26th (a copy of the foundation's statutes may be submitted). • **CIBER:** team members applying to the call must be from at least two groups belonging to CIBER in two different home institutions and one of these two should be a hospital, primary health care or public health administration of the Spanish National Health System (SNS) or Accredited Health Research

	Institutes (Institutos de Investigación Sanitaria acreditados, IIS). Please contact Cristina Rodríguez (cristina.rodriguez@ciberisciii.es) for more information related to CIBER's eligibility. • Applicants not related with the National Health System from non-profit research organizations such as universities, OPIs, technological centres and other private non-profit institutions performing RDI activities in Spain **need to apply for funding to the Agencia Estatal de Investigación (AEI)**, following their eligibility criteria. It is highly recommended to this type of members to integrate in their consortium other Spanish clinical partner (IIS/SNS/CIBER) eligible for funding by ISCIII. **NOT eligible institutions:** - Those declared by **AES 2027** as ineligible to receive funds by ISCIII.
Additional clause regarding available grant	After the evaluation process and based on their budgetary availability and requested funding of selected projects, AEI and ISCIII may exchange applicants to each other in order to optimize the available funds, provided the respective eligibility rules are met.
Eligibility of PI and team members	• Principal Investigators (PI) shall be required to hold a **PhD degree**. • Principal Investigators (PI) can only participate in one project proposal per call. • Principal Investigators (PIs) belonging to an **Accredited Health Research Institutes (IIS) even if they are also affiliated with another institution, must apply ONLY through the IIS as applicant Institution.** • The Principal Investigator (PI) and all members of the research group must belong to the eligible institutions in the call. • Only one PI per beneficiary institution may be funded within the same proposal. • PIs with an ongoing International Collaboration (PCIN) project of the same initiative and purpose that this call and that the project has an ending date after the 31st December 2027 will not be able to apply for this call. This incompatibility will affect only to the PI. And this incompatibility will not apply in the case that the PI participate as coordinator in the new application or in the ongoing project. • For additional incompatibilities please review AES 2027. **Excluded personnel as Principal Investigator (PI):**

	• Those undergoing postgraduate training in Health Specialization (MIR, EIR, FIR, QIR, BIR, PIR, RFIR). • Those undergoing research training (e.g. PhD students, or "Río Hortega" contracts). • Those undergoing postdoctoral training (e.g. "Sara Borrell" or "Juan de la Cierva" contracts). • Researchers contracted by a RICORs and platforms funded by ISCIII.
Eligibility of costs, types and their caps	• **Personnel costs:** - Personnel costs will be eligible for contracts with the needed professional category (superior technician, BSc (grado), MSc (máster), PhD (doctor) for the project development accordingly to the published salary tables in ISCIII's webpage/**AES 2027**. - Contracts for PhD students will be made in the framework of National Subprogramme for Training (scholarships are not eligible). - Personnel costs will not be eligible when corresponding to contracts for PhD students and PhD (doctor) under the frame of Art. 21 and Art. 22 of Law 14/2011, of 1st June, following the specifications established in AES2027 - Personnel costs will be eligible for a maximum of **36 person-months** in total, across all personnel contracts in the project. - Personnel costs will NOT be eligible when they correspond to civil servants or the equivalent personnel (as specified in the Art. 3.4 of **AES 2027** either employed by the beneficiary entities or belonging to the research team. - Personnel costs will be eligible when corresponding to contracts under the frame of Art. 23bis of Law 14/2011, 1st June, following the specifications established in **AES 2027**. • **Other eligible costs:** Current costs, small scientific equipment, disposable materials, travelling expenses, complementary expenses (use of central and general research support services of the beneficiary entity), publication and dissemination of results and other costs as included in **AES 2027** that can be justified as necessary to carry out the proposed activities. • **Overheads,** according to **AES 2027** (25%) • **Double funding** of the same concept is not allowed. • National applications will be required by ISCIII.

Submission of the proposal at the national level	Due to administrative and legal regulations, the Institute of Health Carlos III establishes the **end of October 2027** (tentative date) as the national deadline for the decision on fundable project consortia which includes Spanish partners to be funded by ISCIII, which must present their national application in the period stated in **AES 2027** (probably September/October 2027). Any concerned applicant in a proposal for which no final decision has been made by the deadline **end of October 2027** (tentative date) could be declared not fundable by ISCIII.
Submission of other information at the national level	As specified by **AES 2027**
Submission of financial and scientific reports at the national level	As specified by ISCIII's instructions (please check ISCIII's webpage).
Submission of a pre-eligibility document needed at national level	In order to expedite the eligibility check process, it is mandatory that all the applicants submit the CVA-ISCIII of the PI. This document shall be submitted by the PI by electronic email before the proposal submission deadline to: anagarcia@isciii.es.
Requirements on data and repositories	• Researchers funded by ISCIII must make public the human genomic data, as well as relevant data (phenotype and exposition data) generated inside the funded project and will use open access repositories. Researchers must also make public all the necessary information for the interpretation of these genomic data, including lab protocols, data instruments survey tools. Regarding genomic data it is understood: association of complete genomes (GWAS), matrixes of polymorphism of a single nucleotide (SNP) and sequence of genome, and transcriptomic, metagenomic, epigenomic and gene expression data. The researchers whose projects are funded by ISCIII are recommended to store their scientific data at the "ELIXIR Core Data Resources", or if non-European repositories or data bases are to be used they must be certified by ELIXIR or the US National Center for Biotechnology Information (NCBI). • ISCIII may not fund any project that may require a repository and/or a data base without a plan ensuring sustainability and decommissioning after the end of funding.
Requirements for clinical studies	Spanish groups that are involved on the performance of a clinical trial in the proposal, are recommended to include in their team a member from their scientific node of the EU Clinical Trials Network (SCReN or ECRIN-ERIC) or if it does not exist, a member from the personnel of their Clinical Research Supporting Platform of their institutions (UIC).
Use of Research infrastructures and platforms	Researchers funded by ISCIII are encouraged to make use of the resources available through the European Research Infrastructures and the Spanish Platforms funded by ISCIII for supporting the biomedical and health R&I.

Acknowledgements	Any publication, data base, product or event protected with IPR or not, resulting from the granted project must acknowledge “Award no. XX by Instituto de Salud Carlos III (ISCIII) through “La Acción Estratégica en Salud (Líneas Estratégicas de Investigación en Salud 2024-2027)” 2027 and within the ERA4Health Partnership” even after the end of the project, including other specific acknowledgments that could be requested by ISCIII to the granted project. For more information, please see ISCIII’s ROR here.

Taïwan

Country	Taïwan
Funding organisation	National Science and Technology Council (NSTC)
National contact person	Dr. Ching-Mei Tang Email: cmtom@nstc.gov.tw Tel: +886-2-2737-7695
Funding commitment	810 000€
Anticipated number of fundable proposals	3
Maximum/ Minimum funding per grant awarded to a project partner	-The maximum amount per year per project is €90,000.00 (about NTD3,000,000). -The decision regarding the exact amount of the grant is dependent on the result of the NSTC's internal reviews. -The number of grants of every principal investigator must comply with NSTC's regulation of the max number of two international cooperation projects granted by NSTC for the same duration.
Eligibility of partners	All research institutes, universities, hospitals, public organisations in Taiwan endorsed by the National Science and Technology Council (NSTC) as eligible institutions
Eligibility of costs, types and their caps	Including personnel, consumables, hosting expenses for foreign researchers, and travel expenses for international destinations-joint research & overseas studies, for more information please refer to: https://www.nstc.gov.tw/folksonomy/list/f6d5c23c-b3ce-438e-911b-12a705dbac5a?l=ch
Submission of the proposal at the national level	No official national application is needed in the pre-proposal or full proposal phase. But must notify the national contact person in the National Science and Technology Council of your submission to the ERA4Health joint transnational call via email, together with your application as an attachment.
Submission of other information at the national level	-Taiwanese project partners shall submit a proposal to the NSTC for national financing after the project has been selected and approved for funding through the ERA4Health evaluation and selection process. -The proposals are required to be submitted to NSTC for funding as soon as possible as the internal process of the NSTC generally takes 6 months.
Submission of financial and scientific reports at the national level	please refer to: https://www.nstc.gov.tw/folksonomy/list/f6d5c23c-b3ce-438e-911b-12a705dbac5a?l=ch
Further guidance	

The Netherlands

Country	Kingdom of the Netherlands (NL)
Funding organisation	Dutch Research Council (NWO)
National contact persons	Dr. Joyce Putters, ERA4Health@nwo.nl , +31 30 6001 399 Dr. Martijn de Wilde, ERA4Health@nwo.nl , +31 70 3494 410
Funding commitment	€ 2,500,000 in total
Anticipated number of fundable proposals	At least 6
Maximum funding per grant awarded to a project partner	€ 400,000
Eligibility of partners	An application for funding from NWO may consider the following roles: - *National main applicant* (mandatory): the applicant who leads the application to NWO and is the foreseen national project leader, in case a project is granted. - *National co-applicant* (optional): national applicants in addition to the national main applicant with an active role and responsibility in realising the project and requesting funding from NWO. A researcher may only request NWO funding for one project (part of a European consortium) in this Call for proposals, either as national main applicant or national co-applicant within an application for NWO funding. **National main applicants** To be eligible to submit a proposal, researchers must be employed for an indefinite period (with the associated employment contract) or have a tenure track agreement at any of the following research organisations: • universities and universities of applied sciences, as described in Section 1.8, subsection 1 of the Dutch Higher Education and Research Act, or universities referred to in the Policy Rules for Universities in the Kingdom of the Netherlands; • university medical centres, as described in Article 1.13, paragraph 1 of the Higher Education and Scientific Research Act; • KNAW institutes and NWO institutes; • TO2 institutions[19]; • Netherlands Cancer Institute; • Max Planck Institute for Psycholinguistics in Nijmegen; • Naturalis Biodiversity Center; • Advanced Research Centre for NanoLithography (ARCNL);

[19] The TO2 Institutions are Deltares, NLR, TNO, WUR and MARIN.

- Princess Máxima Center

Researchers employed at a university of applied sciences and researchers employed at a TO2 institute may also submit as a national main applicant if they have at least a salaried position for a limited period of time.

Individuals with a zero-hour or fixed-term employment contract (other than a tenure track appointment) cannot submit a proposal. Applicants with a part-time appointment must ensure adequate supervision of the project and all project members for whom funding is requested.

It may be that the national applicant's tenure track employment contract ends before the intended completion date of the project for which grant funding is being requested, or that the national applicant's tenure agreement ends before this date due to their reaching retirement age. In such cases, the proposal must include a statement from the employer. In this statement, the research organisation in question guarantees that the project and all project members for whom funding is being requested will receive adequate supervision for the full duration of the project.

National co-applicants

All requirements regarding the employment contract described under ´National main applicant', also apply to national co-applicants. National co-applicants must be affiliated with a research organisation either:

1. eligible as a national main applicant (see above), or;
2. with other research organisations as described in Article 1.1, paragraph 4 of the NWO Grant Rules 2024 that comply with the following cumulative conditions.

The organisation must:

- be established in the Netherlands;
- be a foundation, organisation or legal entity established and governed by public law (in Dutch: publiekrechtelijke rechtspersoon) (all other legal forms, including private and public limited companies, are excluded);
- have as its primary goal the independent conduct of its own fundamental research, industrial research or experimental development or with widely disseminating the results of those activities through teaching, publications or knowledge transfer; be able to state that the organisation keeps separate accounts regarding economic/non-economic activities and that undertakings with decisive influence on the organisation do not enjoy preferential access to the organisation's results.

Note: Prior to submission of a pre-proposal NWO will assess whether an organisation complies with Article 1.1, paragraph 4 of the NWO Grant Rules 2024 and is thus eligible to participate as national co-applicant based on the above conditions. This assessment also helps to ensure NWO's compliance with regulations prohibiting state aid.

To enable the assessment to be carried out, the intended national co-applicant's organisation must submit the following documents by email to

	era4health@nwo.nl no later than 10 working days before the submission deadline of the pre-proposal (i.e. by 5 January 2027**,** 14:00:00 CET): • a recent extract from the Chamber of Commerce; • a deed of establishment and/or current articles of association; • the most recently available annual accounts, including an audit report[20]; • a completed Research Organisation Statement, which is available on the funding page of this Call for proposals. These documents must be provided in English or in Dutch. Other relevant documents may also be included. NWO may also request additional information if the above documents do not allow for adequate determination of the organisation's eligibility to act as national co-applicant. If in a full proposal national co-applicants are added to the consortium who are not affiliated with any of the research organisations listed above, these new national co-applicants must be assessed based on the same conditions. Again, the intended national co-applicant's organisation must submit at least the above-mentioned documents by email no later than 10 working days before the submission deadline of the full proposal (i.e. by 25 May 2027, 14:00:00 CEST). If the intended national co-applicant's organisation has already been assessed and found to comply with these conditions as part of a different NWO programme, please contact NWO at the above email address well before the applicable deadline to determine whether further assessment is necessary. If the intended national co-applicant's organisation fails to submit the documents required for assessment on time, NWO will not accept the organisation as national co-applicant. If a research organisation was already assessed and approved as a national co-applicant before submitting the pre-proposal, there is no need to have it assessed again for the submission of the full proposal.
Eligibility of costs, types and their caps	The available budget modules are: ***1. Personnel:*** Salary costs can be claimed for the following positions: *1.1 Postdoc*: at least 1 position, for at least 12 months, for at least 0.5 fte, according to UNL or UMCNL rates, a benchfee is available; *1.2 Non-scientific personnel (NWP)*: according to UNL or UMCNL rates; *1.3 Research leave*: max. 10% of the grant amount, according to UNL or UMCNL rates. *1.4 Personnel at universities of applied sciences, TO2 institutes and other organisations:* using the Government Tariff Manual (HOT), Table 2, under 2.2 'average total salary cost per salary scale', column 'Hourly rate productive hours, excluding VAT' ***2. Materials:*** For project-specific material costs, up to 25% of the grant amount. Subsequently, up to 50% of the material budget can be used for

[20] No audit report is necessary for organisations not legally required to have their annual accounts audited. However, such organisations must be able to provide proof of exemption from this legal requirement.

	work by third parties. Engagement of students may be included here according to the usual internship fee or HOT rates[21]. ***3. Knowledge utilisation***: For activities that promote the use of knowledge from the research, mandatory and at most 20% of the grant amount. ***4. Project management:*** Up to 5% of the grant amount. Please note the following: - An application for NWO funding has one national main applicant, responsible for research and financial management. National co-applicants within an application for NWO funding are allowed. - Researchers employed at a university in the Kingdom of the Netherlands, umc or a research organisation, as referred to in Article 1.1, first paragraph, subparagraphs c to h of the NWO Grant Rules 2024 may not apply for a scientific or post-doc position for themselves. - PhD positions cannot be applied for in this call, due to the maximum project duration of 3 years. - Overhead costs are not eligible for NWO funding A detailed "Explanation of budget modules and indexing" can be found on the NWO funding page of this Call for proposals. Do not hesitate to contact the national contact point in case of questions.
Submission of the proposal at the national level	No separate submission of the proposal at national level is required.
Submission of other information at the national level	It is recommended to use the NWO budget template in the pre-proposal stage to confirm eligibility of budget items and correct use of tariffs. For full proposals, it is mandatory to submit the NWO budget form for the funding requested at NWO at the time of the transnational deadline to era4health@nwo.nl.
Submission of financial and scientific reports at the national level	Submission of financial and scientific reports at national level is required in accordance with the rules of NWO. Granted consortia will be informed.
Further guidance	The NWO Grant Rules 2024 and the Approval of Funding for Scientific Research are applicable to all applications for NWO funding. Any arrangements made regarding the grant from NWO must comply with the NWO Grant Rules 2024 and the European legislation on state aid. Once proposals are recommended for funding on a transnational level, the consortia will be notified by the Joint Call Secretariat (JCS) and subsequently, the national granting process will be initiated by NWO. Under the Dutch General Administrative Law Act, any interested party has the right to lodge an objection to the decision taken by NWO within six weeks of the date of the decision letter. Further information about the objection's procedure can be found on the NWO website: https://www.nwo.nl/en/lodging-an-objection. NWO will, if necessary, apply a one-off indexation of personnel costs when awarding a grant. The current UNL/UMCNL/HOT rate on the national decision date applies. Please refer to the "Explanation of budget modules and indexing" on the NWO funding page, for more information on indexing.

[21] All activities included in this budget module must fit the European Commission Definition of 'knowledge transfer activities' in the State aid framework for research and development and innovation (OJ 2022, C 414).

	As stipulated in the NWO Grant Rules, Article 3.2, paragraph 2, the project cannot start until the conditions set out in the grant award decision regarding the start of the project are met. Please note, these conditions will include a signed Consortium agreement by all partners in the transnational project.

Türkiye

Country	Türkiye
Funding organisation	TUBITAK
National contact person	Şükran Alpdemir sukran.alpdemir@tubitak.gov.tr
Funding commitment	600 000 Euros
Anticipated number of fundable proposals	2-3 projects
Maximum/ Minimum funding per grant awarded to a project partner	Up to 200 000 Euros per project, max. 100 000 Euros for public institutions and max. 200 000 Euros for private companies with 60% funding of the eligible costs for large companies and 75% funding of the eligible costs for SMEs (these amounts do not include extra payments, please refer to the related TUBITAK website for further information).
Eligibility of partners	For further information about application rules and procedures, please refer to the related TUBITAK website.
Eligibility of costs, types and their caps	For further information about application rules and procedures, please refer to the related TUBITAK webpage.
Submission of the proposal at the national level	Yes
Submission of other information at the national level	Yes
Submission of financial and scientific reports at the national level	Yes
Further guidance	Participants from Türkiye should also submit their proposals to TUBITAK electronically via (https://uidb-pbs.tubitak.gov.tr/) for the pre-proposal phase. Only the PIs from successful projects that are listed for funding after the second stage of international evaluation are required to submit their full proposals. **All national applications must be completed via e-signature.**